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ABSTRACT
17β-estradiol (estrogen) has been demonstrated to regulate survival in breast
cancer cells, which is partially mediated by its nuclear receptors ERα and ERβ
and the G protein-coupled estrogen receptor (GPER). We previously established
that estrogen can activate the phosphoinositide 3-kinase (PI3Kinase) prosurvival
pathway via GPER stimulation resulting in PIP3 generation within the nucleus of
breast cancer cells; the mechanism for this is still unclear. PIP3 generation
results in Akt activation, which is known to inactivate FOXO3a, a proapoptotic
transcription factor that translocates from the nucleus to the cytoplasm upon
inactivation resulting in a decrease in proapoptotic gene expression and
consequently an increase in cell survival. Here, utilizing a FoxO3-GFP construct,
we report FOXO3a inactivation as a result of GPER stimulation by E2 and the
GPER-selective agonist G-1 in the estrogen-responsive breast cancer cell line
MCF7 and that ERα is not required. The p110α catalytic subunit of PI3Kinase,
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and the transactivation of the EGFR constitute the mechanism by which GPER
inactivation of FOXO3a occurs. Additionally, E2 and G-1 stimulation of MCF7
cells results in a decrease in caspase activation compared to negative control.
This suggests, in part, that GPER stimulation is required for survival of breast
cancer cells and that GPER expression and FOXO3a localization should be
utilized as prognostic markers in breast cancer treatments. Furthermore, our
results indicate a need for GPER antagonists in GPER positive breast cancers in
order to counteract GPER related prosurvival effects in combination with
chemotherapeutic drug treatments.
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CHAPTER 1

1. Introduction
1.1. Estrogen Synthesis
Estrogens are members of the steroid family of hormones that includes
testosterone, glucocorticoids, mineralcorticoids, and progesterone. These
hormones regulate physiological processes involved in the development and
maintenance of an array of tissue types in both males and females. Estrogens
function as the primary female sex hormone and occur in three forms in nature:
estriol (E3), estrone (E1) and the most biologically active 17β-estradiol (E2)
(Figure 1.1). In females, estrogens are primarily produced by the ovaries in
response to Follicle Stimulating Hormone (FSH) stimulation but are also excreted
in small amounts by the liver, the breasts, the adrenal glands and fat cells.
GnHR, the gonadotropin releasing hormone, is secreted from the hypothalamus
and binds to the GnHR receptor in the anterior pituitary, triggering the release of
FSH and Luteinizing Hormone (LH) (Bliss et al., 2010). LH goes on to stimulate
production of androgens in females. It does this by acting on the theca interna
cells in the ovary, to stimulate the conversion of cholesterol to progesterone, and
finally to androstenedione. Androstenedione then enters neighboring granulosa
cells in the ovary. FSH binds to receptors on the granulosa cells, stimulating the
expression of aromatase enzymes that convert androstenedione to testoserone.
Finally, testosterone is converted via aromatase into 17β-estradiol (E2). E2 plays
a critical role in the development of the female reproductive organs and
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secondary sex characteristics. In males, it is primarily produced by the testes
and is essential for reproductive development and function.
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Figure 1.1. Physiological Estrogens. Chemical structures of the three naturally
occurring estrogens.
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1.2. Estrogen Function
E2 functions as the main female sex hormone; however there are additional
targeted effects of E2 throughout the body other than its role in development and
maintenance of female reproductive organs. E2 is lipophilic and can cross both
the plasma membrane and blood brain barrier. Its concentration within the brain
was initially discovered using tritium-labeled steroid hormones that revealed
estrogen-concentrating cells in the pituitary gland, the hypothalamus and other
brain regions (Lee and Pfaff, 2008). Some of estrogen’s effects within the brain
include neuronal cell proliferation and survival, as well as synaptogenesis during
a sensitive developmental period that establishes the sexually differentiated brain
(Lee and McEwen, 2001).
Estrogen has also been shown to have cardiovascular effects. One instance of
these effects has been demonstrated in cardiomyocytes, where estrogen was
found to prevent cardiac myocyte death. Estrogen is able to prevent apoptosis in
these cells by modulating the two major isoforms of p38 MAPK (α inactivation
and β activation), and also by activation of PI3Kinase, which initiates prosurvival
pathways (Kim et al., 2006). Another example of estrogen having cardiovascular
effects is its ability to modulate the lipid profile by decreasing low-density
lipoprotein (LDL) and increasing high-density lipoprotein (HDL). Higher levels of
HDL have been associated with improved cardiac health (although the
mechanism is not entirely clear), and the presence of estrogen and these
increased HDL levels have been shown to be cardioprotective in pre-menopausal
women. However, if cardiac damage is already present in post-menopausal
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women, estrogen hormone therapy should be administered with statins (Barton,
2013).
Despite these diverse effects, estrogen’s main function occurs within the estrous
cycle. Mammogenesis (mammary growth) occurs minimally until puberty is
reached. The onset of puberty triggers rapid activation of ductal elongation and
branching, which is under strict control of hormones. As the estrous cycle
continually repeats, in addition to during pregnancy, the complexity of the
structure of the mammary glands increases (Pelekanou and Leclercq, 2011).
When these normal growth pathways are not regulated and additionally because
of genetic mutations, breast cancer can occur. Estrogen’s regulation of
mammary growth events, as well as its other effects in the body is mediated by
specific estrogen receptors.

1.3. Estrogen Receptors and Genomic Signaling
In the late 1950s, Elwood Jenson discovered and began characterizing a protein
that was able to bind E2 (Toft and Gorski, 1966) (Nilsson et al., 2001). E2 was
known to stimulate growth; however the accepted mechanism at the time was
that E2 was an enzyme cofactor in a reversible oxidation/reduction reaction
leading to hydrogen transfer from NADH or NADPH and that this biochemical
reaction resulted in growth (Jensen et al., 2010). In order to determine
estrogen’s distribution in tissues, physiological concentrations of tritium-labeled
estrogen was administered to immature female rats resulting in uptake in the liver
and the kidneys, as well as prolonged uptake in the uterus and vagina. The
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tritiated E2 was determined not to be chemically altered, contrary to the proposed
mechanism of action, suggesting that E2’s effects were a result of binding to
another protein. This protein was originally called estrophillin, and suggested to
bind E2 resulting in the growth response (Jensen et al., 2010). Jenson et al.
were eventually able to clone the receptor by first producing the antibody to the
receptor, then adding the tritiated E2 hormone marker to form a radioactive
immune complex. This would yield a larger complex that was able to be
separated out utilizing sucrose density centrifugation. The fractions obtained
from the sucrose gradient centrifugation contained high levels of ER mRNA,
which enabled the production of cDNA libraries (Green et al., 1986). Another
estrogen binding protein was later cloned from a rat prostate cDNA library
(Kuiper et al., 1996). The first receptor became known as ERα, while the latter
was named ERβ.
In the absence of ligand, ERs are localized predominantly within the nucleus,
while a small percentage is localized to the cytoplasm. Heat shock protein (HSP)
chaperones keep the receptors in an inactive conformation as well as stabilize
them from degradation. Estrogen is able to diffuse through the plasma
membrane, enter the cell and diffuse into the nucleus where it can bind ERα and
ERβ. Upon E2 binding, conformational changes in these receptors occur,
leading to the dissociation of inactivating proteins, dimerization and translocation
of cytoplasmic receptors to the nucleus and/or nuclear receptors to DNA. ERs
bind to estrogen response elements (EREs) in DNA and act as transcription
factors. ERα has been shown to modify genes that encode for proteins involved
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in cell growth and proliferation. ERβ’s function is less well characterized, but it
has been suggested in many cases to oppose the functions of ERα (Sanchez et
al., 2013).
ERα and ERβ share similar structures and belong to the steroid/thyroid binding
family of nuclear receptors (Figure 1.2). The most conserved central binding
domain of the estrogen receptors is the DNA binding domain (DBD), which
recognizes its target sequences within DNA and is also important in receptor
dimerization upon ligand binding. The ligand-binding domain (LBD) is located
near the COOH-terminus and mediates ligand binding, receptor dimerization,
nuclear translocation and transactivation of target gene expression. The NH2terminal domain is the least conserved and is variable with respect to both
sequence and length. In nuclear receptors, this domain encodes for a ligandindependent activation function (AF-1), which is involved in protein-protein
interactions and transcriptional activation. The AF-1 of ERα is known to be active
in stimulating receptor gene expression; however the AF-1 of ERβ has been
suggested to have negligible activity. In addition to sequence homology within
the DBD and the LBD, the two ERs have similar affinities for E2 and also bind the
same response elements within DNA.
Estrogen binding to its nuclear receptors leads to receptor dimerization, and
subsequently translocation to DNA where the receptors function as transcription
factors that can bind estrogen response elements (EREs) and modify gene
expression. Which genes are affected by this transcriptional regulation depends
on cell type, the presence or absence of coregulatory proteins, and which ER is
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involved. E2-bound ERs can also bind to other transcription factor complexes
such as Fos/Jun and modulate gene expression of promoters that do not contain
EREs.
In addition to full length ERα, splice variants have been described (Taylor et al.,
2010). These include a 46 kDa protein that is the product of an N-terminal
truncation as well as a 36 kDa variant that has the same N-terminal truncation
with an additional C-terminal truncation (Kim and Bender, 2009) (Chaudhri et al.,
2014). In the absence of the N-terminal transcription activation domain, these
splice variants have been demonstrated to act as inhibitors of ERα-mediated
transcription and to mediate rapid signaling pathways. Although ERβ has many
known splice variants, they are not yet characterized.
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Figure 1.2. Steroid hormone receptor family. The domains starting from the Nterminus (left) to C-terminus (right). NTD = N-terminal domain, DBD = DNA
binding domain. LBD = ligand binding domain. AF = activation function. The
steroid hormone receptor abbreviations are ER – estrogen receptor, GR –
glucocorticoid receptor, PR –progesterone receptor, AR – androgen receptor,
and MR – mineralocorticoid receptor. The numbers to the right are the lengths in
amino acid residues.
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1.4. Estrogen Receptors and Nongenomic Signaling
Estrogen’s earliest cellular effects were in fact described as rapid signaling
events such as second messenger production (cAMP) and regulation of ion
channels (Ca++). In 1975, a Nature article demonstrated rapid calcium uptake in
endometrial cells in response to estrogen (Pietras and Szego, 1975). It was
originally assumed that ERα was responsible for these rapid signaling effects of
estrogen.
In 1997, using differential cDNA library screening, the cDNA library of MCF7
cells, an estrogen receptor positive breast carcinoma cell line, was compared to
the cDNA library of MDA-MB-231 cells, an estrogen receptor negative breast
carcinoma cell line (Carmeci et al., 1997). This technique is utilized to determine
the differential expression of genes in one cell type compared to another. One
cDNA that was more highly expressed in MCF7 cells compared to MDA-MB-231
cells was isolated and the sequence analyzed. When compared to the nucleic
and amino acid sequences found in GenBank/EMBL at NCBI, it was determined
that the open reading frame of the isolated cDNA shared extensive sequence
homology with previously described G protein-coupled receptors (GPCRs). This
orphan GPCR was initially named GPR30 and much later renamed the G
protein-coupled estrogen receptor (GPER). Due to its pattern of expression,
GPER was hypothesized to be involved in physiological responses specific to
hormonally responsive tissues. However at this point, its physiological ligand(s)
were not known and further characterization of this receptor was required.
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GPER has since been more clearly defined as a G protein-coupled receptor
belonging to the family of 7 transmembrane spanning receptors. Most GPCRs
are localized to the plasma membrane. However, our group was able to
demonstrate that GPER is localized predominantly to intracellular membranes
associated with the endoplasmic reticulum and the Golgi apparatus in multiple
cell types (Revankar et al., 2005). This was determined utilizing fluorescence
microscopy techniques to visualize labeled GPER colocalizing with labeled
markers of the endoplasmic reticulum and the Golgi. However, it has more
recently been suggested that in other tissues, such as renal epithelia, GPER is
significantly expressed at the plasma membrane (Cheng et al., 2011). This study
proposed that some cells may regulate GPER’s action by modulating the
subcellular distribution of the receptor between the plasma membrane and the
perinuclear compartment and that this occurs by the process of endocytosis, with
accumulation of GPER in the perinuclear compartment.
There are regions of GPCR receptors that are exposed to the extracellular space
or, as in the case of GPER, to the intracellular cytoplasmic space since it is
localized to the ER. The portions of the receptor flanking the surface of the
membrane along with the transmembrane domains contribute to ligand binding.
The structural and chemical composition of these regions is dependent on the
receptor and this composition essentially forms a binding pocket for its
corresponding ligand. Ligand binding results in receptor activation and
transmission of signals through the membrane via the transmembrane domains.
GPCRs are associated with their canonical heterotrimeric G proteins consisting
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of α and βγ subunits that are bound to the cytoplasmic region of the receptor.
GPCRs essentially function as guanine nucleotide exchange factors (GEFs) that
can activate an associated G-protein by exchanging its bound GDP for a GTP.
The G-protein's α subunit, together with the bound GTP, can then dissociate from
the β and γ subunits to further affect intracellular signaling proteins or target
functional proteins directly depending on the α subunit type. The βγ subunits
together have also been demonstrated to have their own signaling effects.
GPCR stimulation can lead to initiation of such downstream events as the
activation of adenylate cyclase, which results in the production of the second
messenger cAMP (cyclic adenosine monophosphate). cAMP activates multiple
kinases including protein kinase A (PKA). The stimulation of GPCRs and
subsequent dissociation of its G-proteins can also be coupled to effector
molecules such as phospholipases, phosphodiesterases and ion channels
(Prossnitz et al., 2008). Additionally, GPCRs have been demonstrated to
appropriate crosstalk with receptor tyrosine kinases, particularly the EGFR
(George et al., 2013). There is evidence that suggests GPER is coupled to
various G proteins resulting in the activation of multiple downstream signaling
cascades.
It had been previously established that estrogen promotes rapid activation of the
MAPKs ERK-1/2; however, it was unclear whether ERα or ERβ were required. In
2000, the Filardo group determined that E2 activation of ERK was due to GPER
stimulation through transactivation of the EGFR in an ERα-independent manner
(Filardo et al., 2000). The effect was established in SKBR3 cells that express
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GPER but not ERα or ERβ. It was determined that GPER-stimulated ERK-1/2
activation was inhibited by Src family tyrosine kinase inhibitors and heparinbound-EGF (HB-EGF)-neutralizing antibodies. Additionally, pertussis toxin and a
Gβγ-sequestering peptide inhibited GPER-dependent ERK-1/2 activation.
Therefore, it was concluded that GPER signaled through Gβγ-dependent Src
activation ultimately resulting in transactivation of the EGFR following cleavage of
pro HB-EGF by matrix metalloproteinases (Filardo et al., 2000). Although GPER
induces ERK-1/2 activation downstream of EGFR, it also inhibits this effect via
cAMP production resulting from Gαs activation. This dual action of GPER tightly
regulates ERK-1/2 activation, which ensures the potent actions of the MAPKs are
not sustained (Filardo et al., 2002).
Subsequently, our group discovered in 2005 that E2 also activates PI3Kinase as
a consequence of transactivation of the EGFR (Revankar et al., 2005). Using the
PH domain of the downstream effector Akt as a reporter, we concluded
PI3Kinase activation led to nuclear accumulation of its phosphorylated substrate
PIP3. The mechanism for this activity is however still unclear (Figure 1.3).
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Figure 1.3. Estrogen receptor signaling summary. Estrogen is able to diffuse
through the plasma and nuclear membrane in order to bind its canonical ERs
within the nucleus. Estrogen can also bind GPER, which leads to transactivation
of the EGFR and downstream signaling including PI3Kinase activation.
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1.5. PI3Kinase
Lipid kinases have become highly scrutinized because of their association with
growth factor-stimulated pathways, whose overstimulation can result in
cancerous phenotypes when not properly regulated. In particular, the
phosphoinositide 3-kinase (PI3K) family has been extensively investigated. The
PI3K family is divided into four groups (IA, IB, II, and III) according to structural
features and substrate specificity (Figure 1.4) (Vanhaesebroeck et al., 2010).
Class IA of PI3Ks are enzymes that consist of a catalytic p110 domain (p110α,
p110β, and p110δ) and a regulatory p85 domain (p85α, p85β, and p55γ). The
two ubiquitously expressed catalytic domains are p110α and p110β, which are
usually coupled to their respective regulatory subunits p85α and p85β.
PI3Kinase activation occurs when the SH2 domains of the p85 subunit can bind
to phosphorylated tyrosine residues generated by an upstream kinase in order to
release the active catalytic p110 subunit. p110α has been demonstrated to have
a role in growth factor and metabolic signaling as well as being selectively
mutated and overexpressed in a variety of cancers (Foukas et al., 2006). p110β
has been reported to be involved in DNA replication, S phase progression, and
DNA repair (Marques et al., 2009) (Kumar et al., 2010) (Kumar et al., 2011). It
has been suggested that, despite their similar structures and ubiquitous
expression, the differing functions of p110α and p110β are related to their distinct
subcellular localization. p110α has been shown to be primarily localized to the
cytoplasm while p110β is primarily localized to the nucleus.
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When a Class IA PI3K is activated by an upstream signaling event, such as
growth factor receptor activation, the phosphotyrosine residues generated within
the receptor tail can bind to the p85 subunit and free the catalytic domain to
function as a kinase. Activated PI3K converts the membrane phospholipid,
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)triphosphate (PIP3) (Vanhaesebroeck et al., 2010). PIP3 can then bind to the PH
domains of Protein Kinase B (Akt) and 3-phosphoinositide-dependent kinase
(PDK), recruiting these proteins to the membrane. The accumulation of PIP3 is
negatively regulated by the protein phosphatase PTEN, which dephosphorylates
PIP3 back to PIP2. At the membrane, PDK can only phosphorylate the Thr308
residue of Akt. In order to phosphorylate Akt’s additional activation residue
Ser473, it has been suggested that PDK forms a complex with another kinase,
PRK (Datta et al., 1999). The actions of activated Akt include regulating cell
survival by interacting with multiple proteins. One such protein is Bad, a member
of the proapoptotic Bcl-2 family, which has been shown to be phosphorylated and
inactivated by Akt. The human caspase-9 which executes apoptosis was also
shown to be phosphorylated and inactivated by Akt (Datta et al., 1999). A
number of transcription factors, which include members of the forkhead box
(FOX) family, can also be regulated by Akt. The FOX class of transcription
factors are involved in cell fate decisions, proliferation and metabolism. In
particular, FOXO3a, a transcription factor that aids in the production of
proapoptotic genes, is known to be phosphorylated by Akt (Brunet et al., 1999).
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This leads to the exclusion of FOXO3a from the nucleus and subsequently a
decrease in proapoptotic gene expression.
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Figure 1.4. Phosphoinositide 3-kinases (PI3Ks) are divided into three
classes based on their structural and biochemical features. All PI3K catalytic
subunits have a core structure consisting of a C2 domain, a helical domain and a
catalytic domain (Vanhaesebroeck et al., 2010) . (a) Class I use
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) as their substrate and exist
in complex with a regulatory subunit, either a p85 isoform (for p110α, p110β and
p110δ) or p101 or p87 (for p110γ). All p85 isoforms have two Src homology 2
(SH2) domains. p101 and p87 lack SH2 domains. (b) Class II PI3Ks use PtdIns
as a substrate, but might also use PtdIns-4-phosphate (PtdIns4P) under certain
conditions. They lack regulatory subunits but have amino- and carboxy-terminal
extensions to the PI3K core structure. (C) Class III PI3K has one catalytic
member, vacuolar protein sorting 34 (Vps34) which uses PtdIns as a substrate
and binds Vps15.
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1.6. FOX Proteins
In 1990, when the DNA binding motif of the hepatocyte enriched HNF-3
transcription factors was initially being described, it did not resemble any known
binding motif (Lai et al., 1990). However, once the sequence was analyzed, its
110-amino-acid DNA binding domain was discovered to be almost perfectly
conserved with the Drosophila melanogaster forkhead gene (Weigel and Jackle,
1990). Proteins with this conserved domain are now referred to as forkhead box
(FOX) proteins and consist of a large family of more than 100 transcriptional
regulators.
The mammalian forkhead domain is a monomeric DNA-binding domain,
approximately 100 amino acids long, and consists of three α helices and two
characteristic large loops or butterfly-like ‘wings’ (Burgering, 2008). There are
more than 100 members of the FOX family and they are involved in regulating a
number of cellular processes, with roles in development, differentiation,
proliferation, apoptosis, stress resistance and metabolism. They are divided into
19 different subgroups and the 39 human Forkhead proteins are designated by a
capital letter after FOX (FOX for ‘Forkhead Box’ A to S). The FOXO subfamily of
transcription factors is involved in cell fate decisions, proliferation and
metabolism. Other examples of FOX proteins that have a role in development
are FOXC, which is involved in organogenesis and FOXP, involved in language
acquisition and organogenesis (Lehmann et al., 2003).
The FOXO subgroup consists of four members: FOXO1, FOXO3a, FOXO4 and
FOXO6. These proteins are ubiquitously expressed, but vary in their levels of
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expression in different cell types. FOXO1 is more highly expressed in adipose
tissue, while FOXO4 is found in the heart and muscle. FOXO3a has elevated
levels in the brain and liver, whereas FOXO6 is highly expressed in the
developing brain, suggesting a role in neural development. FOXO proteins have
the same DNA binding-domain, which suggests that they should be able to bind
to similar sequences within DNA. The core consensus sequence for FOXO
binding is (5’TTGTTTAC3’) (Furuyama et al., 2000). FOXO3a, 1, and 4 initially
became of interest when they were found at the chromosomal translocations of
tumors. This localization suggested that FOXO proteins may play a role in tumor
development.
FOXO3a, 1 and 4 can be localized either to the nucleus or the cytoplasm
depending on their phosphorylation status, while FOXO6 is predominantly
nuclear and its phosphorylation status only affects its function. When FOXO
proteins are nuclear and functional, they act as transcription factors that regulate
expression of their target genes. FOXO proteins are able to induce cell cycle
arrest by upregulating the cdk inhibitors p27kip and p21, and the Rb family
member p130, which block G1/S phase progression. FOXO proteins can also
promote apoptosis by inducing expression of the proapoptotic Bcl-2 family
member Bim. Bcl-2 family members are involved in MOMP (mitochondrial outer
membrane permeabilization), which induces cytochrome C release and
subsequent events leading to cell death. FOXO proteins can also induce
apoptosis by increasing expression of the death receptor ligand FasL and the
cytokine TRAIL (Accili and Arden, 2004). FOXO protein regulation of gene
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expression that results in inhibition of the cell cycle and apoptosis suggests that
this subgroup of forkhead proteins represents bona fide tumor suppressors.
FOXO proteins are regulated/phosphorylated by Akt. Once Akt is activated by
the PI3Kinase pathway in the presence of growth factor signals, it is presumed to
translocate from the plasma membrane to the nucleus where it phosphorylates
FOXO proteins at specific residues. Akt can phosphorylate FOXO3a, 1, and 4 on
three key regulatory sites Ser253, Ser315 and Thr32 though Ser253 and Thr32
are the preferred sites. FOXO proteins can also be phosphorylated by SGK
(serum and glucocorticoid-inducible kinase), which prefers the combination of
Ser315 and Thr32. In the absence of growth factor signals/activation of the
PI3Kinase pathway, FOXO proteins are localized predominantly to the nucleus,
where they carry out their functions as proapoptotic transcription factors.
However, when the PI3Kinase pathway is stimulated, phosphorylated FOXO
proteins translocate from the nucleus to the cytoplasm. A leucine-rich region
within their C-terminal domains functions as a nuclear export sequence, for which
the 14-3-3 protein is required. 14-3-3 proteins are α-helical molecules that
regulate intracellular signal transduction. The Akt phosphorylation sites at the N
terminus and in the forkhead domain of FOXO proteins create two 14-3-3 binding
motifs and induce FOXO binding to nuclear 14-3-3 proteins (Brunet et al., 2002).
Akt phosphorylation and subsequent binding of the 14-3-3 protein results in
FOXO’s exclusion and transport from the nucleus to the cytoplasm. Once FOXO
proteins translocate to the cytoplasm, they are targeted for degradation by the
ubiquitin-proteasome pathway.
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In addition to Akt, the inhibitor of nuclear factor kappa-B kinase subunit β (IKKβ)
also causes the proteasome-dependent degradation of FOXO factors,
specifically FOXO3a, via phosphorylation at Ser644 (Hu et al., 2004). Since
IKKβ positively regulates NF-ΚB by inactivating its negative regulator IKB, and
phosphorylates FOXO3a for degradation, IKKβ can promote uncontrolled cell
proliferation leading to tumorigenesis.

1.7. PI3Kinase/Akt/FOXO and Cancer
Since the PI3Kinase/Akt/FOXO pathway leads to regulation of cell proliferation,
control of the cell cycle and apoptosis, it is not surprising that dysregulation of
this pathway can result in tumor growth and cancer. The most common
irregularity in this signaling pathway promoting cancer is mutations in PI3KCA,
which is the gene encoding the p110α catalytic domain of PI3Kinase (Janku et
al., 2014). Three different mutations have been attributed to PI3KCA-induced
cancer. The first, H1047R, occurs in the activation loop of the catalytic domain
and results in constitutive kinase activity. The other two, E542K and E545K, are
located in the helical domain of the catalytic subunit and have been determined
to block the ability of the regulatory domain to keep the catalytic domain in an
inactive state. All three of these mutations result in the over-activation of
PI3Kinase, leading to uncontrolled cell proliferation, survival and tumorigenesis.
The Cancer Genome Atlas (TCGA) reports that the PI3KCA gene is mutated in
53% of endometrial cancers, 35% of breast cancers, 23% of cervical cancers,
21% of gastric cancers, 20% of head and neck cancers, 20% of colorectal
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cancers, 15% of lung squamous cell cancers, and 10% of glioblastomas as well
as in other tumor types (Polivka and Janku, 2014). There are many selective
inhibitors for PI3Kinase currently in clinical trials.
Another constituent of this signaling pathway whose function can be disrupted
and can cause cancer is PTEN (phosphatase and tensin homolog). PTEN has
been deemed a tumor suppressor because of its ability to dephosphorylate PIP3,
which prevents Akt binding and subsequent activation. The disruption of PTEN’s
tumor suppressor ability can be attributed to mutations, deletions, transcriptional
silencing and epigenetic changes. For example, the zinc-finger transcription
factor sal-like protein 4 (SALL4) represses PTEN transcription by recruiting an
epigenetic repressor complex to the PTEN locus. Additionally, hypermethylation
of PTEN’s promoter causes it to be epigenetically silenced and this pathological
feature is observed in many cancers (Song et al., 2012). Furthermore, PTEN
splice variants retaining introns 3 and 5 have been found in sporadic breast
cancer. This result suggests that alternative splicing of PTEN could also
contribute to the development of breast cancer.
Downstream of PI3Kinase activation, Akt activation results in cell proliferation
and survival through inactivation of FOXO and many other proteins. The 3
different isoforms of Akt (1, 2, and 3) exhibit approximately 80% sequence
homology. Akt was initially discovered to be overexpressed in ovarian cancers,
as well as in pancreatic tumors and other human malignancies (Polivka and
Janku, 2014). In addition to overexpression, there are known activating
mutations that consist of the amino acid substitution of E17K in Akt’s lipid binding
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domain that keep it localized to the membrane, therefore increasing its ability to
be activated by membrane localized PDK. These mutations have been found in
ovarian, breast and colorectal cancers. Akt inhibitors are being developed that
allosterically inhibit this kinase.
Activated FOXO3a is a proapoptotic transcription factor within the nucleus, and it
has been referred to as a tumor suppressor. FOXO3a is a downstream target of
PI3Kinase/Akt, which makes it an attractive prognostic marker in cancers. As
discussed above, PI3Kinase hyperactive mutations are found in breast cancer
and would result in cytoplasmic localization and inactivation of FOXO3a. Chen et
al. suggested that nuclear FOXO3a is correlated with poor prognosis in breast
cancer. They propose that the uncoupling of sustained nuclear FOXO3a and
PI3Kinase/Akt signaling results in an inactive nuclear FOXO3a which results in
cancer progression (Chen et al., 2010). In contrast, Hashaby et al. correlated
poor prognosis with cytoplasmic localization of FOXO3a in breast cancer patient
tissue samples and nuclear localization with good prognosis (Habashy et al.,
2011). FOXO proteins have been shown to interact with a well-known tumor
suppressor, p53, within the nucleus. This interaction has been suggested to lead
to coordinated tumor suppression because p53 and FOXO proteins can regulate
some of the same genes, such as p21, a cell cycle inhibitor (van der Horst and
Burgering, 2007). FOXO proteins also interact with SMADs to regulate target
gene expression leading to tumor suppression. SMADs respond to transforming
growth factor beta (TGF-β) and translocate to the nucleus in order to regulate
their antiproliferitive target genes. Additionally, FOXO proteins can interact with
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β-catenin and this association is suggested to sequester β-catenin, inhibiting
cellular adhesion, which promotes tumor growth.

1.8. Breast Cancer
Breast cancer is one of the leading causes of cancer-related deaths in women.
In recent years, the incidence has decreased due to early detection and more
specialized treatment methods. Characterization of the receptor status of a
patient’s tumor enables physicians to decide the best course of treatment on a
more individual basis. It has been recommended by the American Society of
Clinical Oncology and the College of American Pathologists that all invasive
breast cancer patient samples be tested for their ER, PR and HER2 receptor
status (Anderson et al., 2014). The major tumor subtypes can be classified into
four groups based on their receptor status. Luminal A is defined as ER+, and/or
PR+, and HER2- and is considered to be the least invasive with a generally
higher survival rate while Luminal B (ER+, and/or PR+, HER2+ or HER2- with
high Ki67) is characterized by higher proliferation rates and a poorer survival
prognosis. Both Luminal A and B are able to respond to endocrine therapy.
HER2-overexpressing tumors have a higher grade, spread more aggressively,
even to lymph nodes, and often respond to HER2-targeted therapies. Lastly,
triple negative or basal-like breast cancer (TNBC) does not express any of the
above receptors and because of this has no targeted therapies.
Estrogen’s role in breast cancer is linked to its receptor status. If estrogen levels
are elevated, it can lead to overstimulation of the canonical ERα receptor when
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present, resulting in uncontrolled cell proliferation, i.e. cancer. However, ERα’s
expression in certain breast cancers can also allow it to be targeted by the antiestrogen, tamoxifen. Tamoxifen, a SERM (Selective Estrogen Receptor
Modulator), was introduced in the 1970s and is frequently used in premenopausal woman diagnosed with ER-positive cancer. Tamoxifen is able to
antagonize ERα by inhibiting its AF2 domain and therefore reducing genomic
signaling that leads to uncontrolled proliferation (Johnston and Yeo, 2014). In
post-menopausal women it is becoming more common to use aromatase
inhibitors (AIs), which block the overall production of estrogen. However,
SERMS such as tamoxifen have also been shown to act as agonists for the more
recently discovered estrogen receptor, GPER, which could have the opposite
effect on an estrogen-responsive tumor that is ER-negative.
It had been previously established that approximately one in four patients did not
respond to tamoxifen therapy with various reasons implied such as ER
expression heterogeneity, etc. As of 2002, GPER had been demonstrated to be
an estrogen-responsive receptor that induced rapid signaling effects resulting in
proliferation of cells in the absence of the classical ERs (Filardo, 2002). In 2006,
to determine whether GPER could be related to unsuccessful hormone therapy in
breast cancer, a study was performed to assess the relative tissue distribution of
GPER, ER, and PR in intraductal and invasive ductal carcinoma, correlated with
other known histopathologic markers of disease (Filardo et al., 2006).
Approximately 60% of the samples expressed GPER, with roughly 50% of ERαpositive tumors expressing GPER. This would indicate an intact E2 signaling
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pathway is also present in ERα-negative tumors that express GPER. This study
also demonstrated increased tumor size and the presence of distant metastases
correlated with increased GPER expression. In 2010, it was established that
tamoxifen resistance in MCF-7 breast cancer cells, which are ER+ and GPER+,
was dependent on GPER expression (Ignatov et al., 2010). Additionally, this
study confirmed a role for tamoxifen as a GPER agonist. This would suggest
that GPER expression could be a marker for the occurrence of tamoxifen
resistance in ER+ breast cancer and that targeting GPER in addition to ERs
could rectify this problem.

1.9. GPER-selective ligands
Estrogen binds to the classical canonical receptors, ERα and ERβ. It has also
been established that GPER is an estrogen receptor that can bind E2.
Furthermore, GPER and ERβ can bind the ERα antagonists ICI 182,780,
tamoxifen and raloxifene (Barkhem et al., 1998)(Prossnitz and Barton, 2014).
This makes it more challenging to delineate GPER’s response when all three
receptors are present. In order to determine the cellular effects in response to
stimulation of GPER, a GPER-selective agonist was generated. This was
accomplished by screening a large library of chemical compounds to discover
those that could bind selectively to GPER (Bologa et al., 2006).
A virtual screen of a library of approximately 10,000 GPCR-associated
compounds was analyzed to assess their structural similarity to E2. Based on
the results, the top 100 compounds were tested for activity toward GPER using a
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competition-binding assay. One compound, later named G-1 (Figure 1.5), was
subsequently identified as a selective GPER agonist. G-1 competitively
displaced binding of fluorescent E2 (E2-Alexa) in GPER-transfected cells. G-1
was determined to have an inhibition constant (Ki) of 11nM for GPER, whereas
the Ki for E2 binding GPER is 5.7 nM (Bologa et al., 2006). No significant affinity
of G-1 for ERα or ERβ was observed. The specificity of G-1 as an agonist was
confirmed by its ability to promote intracellular calcium immobilization in COS-7
cells transfected with GPER, but not in COS-7 cells transfected with the
canonical ERs.
A GPER-selective antagonist was later identified and named G15 (Figure 1.5).
G15 antagonizes E2-dependent GPER activation in vitro and in vivo, based on
data from a study using an established assay of E2-induced murine uterine
proliferation (Dennis et al., 2009). G15 exhibits low-affinity cross reactivity to
ERα at concentrations of 10µM and above. G36 (Figure 1.5) was subsequently
synthesized and exhibited a higher selectivity for GPER over ERα than G15
(Dennis et al., 2011). These selective agonist and antagonists are essential tools
for studying GPER specific effects in cells and in vivo.
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Figure 1.5. GPER-selective ligands. Chemical structures of GPER‐selective
agonist (G‐1) and antagonists (G15 and G36).
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Rationale
In addition to its genomic effects, estrogen has been shown to mediate rapid
signaling events in diverse cell types, including breast cancer cells. These
effects are, in part, mediated through its classical soluble nuclear receptor, ERα.
However, in 2000 a novel estrogen receptor known as GPR30 (currently named
GPER) was demonstrated to activate ERK-1/2 in response to estrogen. In 2005,
our lab demonstrated PI3Kinase activation was also initiated by estrogen
activation of GPER. The mechanism of this activation and its downstream
effects are currently not well understood.

Hypothesis
Our lab has previously demonstrated that the estrogen receptors ERα and GPER
can activate PI3Kinase when exogenously and endogenously expressed.
FOXO3a has been shown to be inactivated by PI3Kinase-activated Akt via a
phosphorylation event leading to the exclusion of FOXO3a from the nucleus.
Therefore, we hypothesize that estrogen receptor stimulation in MCF7 cells
expressing both ERα and GPER can inactivate FOXO3a through activation of
PI3Kinase by GPER.

Specific Aims
Aim 1: Determine the effects of estrogen induced PI3Kinase activation.
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Aim 2: Determine the mechanisms responsible for estrogen regulation of
FOXO3a.

Aim 3: Investigate the resulting effects of FOXO3a regulation by estrogen
receptors.
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CHAPTER 2

2. GPER activation leads to FOXO3a inactivation in MCF7 breast cancer
cells.
2.1. Abstract
In addition to its genomic effects, the steroid hormone estrogen has been shown
to mediate rapid signaling events in diverse cell types, including breast cancer
cells. These effects are, in part, mediated through its canonical soluble nuclear
receptor, estrogen receptor α (ERα). However, a novel estrogen receptor known
as GPER (G-protein coupled estrogen receptor, previously termed GPR30) has
been demonstrated to activate multiple signaling cascades in response to
estrogen. We previously established that PI3Kinase-mediated production of
PIP3 in the nucleus is initiated by estrogen-mediated stimulation of GPER. The
mechanism of this activation and its downstream effects are not well understood.
Here we describe that estrogen and the GPER-selective agonist G-1 induce
rapid signaling through GPER to activate PI3Kinase. This activation occurs via
the transactivation of EGFR leading to the activation of the p110α subunit of
PI3Kinase resulting in the subsequent Akt-mediated phosphorylation of the
transcription factor FOXO3a. PI3Kinase inactivates the proapoptotic protein
FOXO3a, resulting in its translocation from the nucleus to the cytoplasm. The
nuclear exclusion of FOXO3a by GPER activation suggests GPER signaling
results in prosurvival cellular effects in breast cancer cells.

32

2.2. Introduction
Estrogen is the main female sex hormone involved in an array of physiological
processes. The most biologically active form of estrogen, 17β-estradiol (E2), is
primarily produced in the ovaries of females and the testes of males, and is
involved in the development, maintenance and function of the reproductive
organs in both. In females, estrogen also regulates mammary growth and this is
dependent on the estrous cycle. When normal mammary growth pathways are
not properly regulated, and/or genetic mutations occur, breast cancer can
develop.
Estrogen’s actions are mediated by its classical nuclear receptors ERα and ERβ.
These actions include, but are not limited to, E2 binding to its receptors, which
then dimerize and function as transcription factors that bind to EREs (Estrogen
Response Elements) within DNA to modulate gene expression (Kumar and
Chambon, 1988). Activated ERα modifies the production of genes, which results
in the expression of proteins that can promote cell growth and proliferation.
ERβ’s function is less well characterized, but it has been suggested in many
cases to oppose the functions of ERα (Sanchez et al., 2013). More recently,
another estrogen receptor was discovered, originally named GPR30 and now
GPER (G-protein coupled estrogen receptor) (Carmeci et al., 1997). GPER has
been demonstrated to be responsible for estrogen’s activation of the MAP
Kinases ERK-1/2 in ERα- and ERβ- negative cells (Filardo et al., 2000).
Estrogen’s activation of ERK-1/2 is dependent on the epidermal growth factor
receptor (EGFR), which is transactivated by GPER stimulation. Transactivation
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of EGFR by GPER stimulation occurs in a Src-dependent manner via the release
of Heparin-bound epidermal growth factor (HB-EGF), which binds and activates
the EGFR. Subsequently, the Prossnitz laboratory discovered in 2005 that E2
can activate PI3Kinase, also as a consequence of transactivation of the EGFR
(Revankar et al. 2005). Using the PH domain of the downstream effector Akt
(Protein Kinase B) as a reporter, they concluded PI3Kinase activation led to
nuclear accumulation of its phosphorylated substrate PIP3. The mechanism for
this is still unclear.
The enzyme PI3Kinase converts the membrane phospholipid,
phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinositol-(3,4,5)triphosphate (PIP3). PI3Kinase consists of a catalytic domain and a regulatory
domain. The two ubiquitously expressed catalytic domains are p110α and p110β
and are usually coupled to their respective regulatory subunits p85α and p85β,
respectively (Vanhaesebroeck et al., 2010). PI3Kinase activation occurs when
the SH2 domains of the p85 subunit bind to phosphotyrosine residues generated
by an upstream kinase in order to release the active p110 catalytic subunit.
p110α has been demonstrated to have a role in growth factor and metabolic
signaling as well as being selectively mutated and overexpressed in a variety of
cancers (Foukas et al., 2006). p110β has been reported to be involved in DNA
replication, S phase progression, and DNA repair (Kumar et al., 2011).
Downstream of PI3Kinase activation, PIP3 recruits Akt leading to Akt
phosphorylation and activation by PDK. Akt has many substrates such as the
proapoptotic protein Bad and glycogen synthase kinase-3 (GSK-3). The
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phosphorylation of these substrates by Akt can lead to cellular responses
including cell survival by inactivating Bad and the regulation of metabolism by
inhibiting GSK-3 (Datta et al., 1999). Additionally, the proapoptotic transcription
factor, FOXO3a is inhibited by Akt to promote cell survival (Zheng et al., 2000).
The forkhead box O (FOXO) class of transcription factors is involved in cell fate
decisions, proliferation, and metabolism. The FOXO transcription factors are
characterized by their ‘winged helix’ DNA binding domains. Since their functions
are regulated by pathways found to be deregulated in cancer, FOXO proteins are
generally characterized as tumor suppressors (Burgering, 2008). FOXO proteins
can be regulated by Akt, specifically FOXO3a. FOXO3a is a transcription factor
that aids in the production of proapoptotic genes, and is phosphorylated by Akt
(Zheng et al., 2000). Akt preferentially phosphorylates FOXO3a at Ser253 and
Thr32, leading to the exclusion of FOXO3a from the nucleus and a decrease in
proapoptotic gene expression (Brunet et al., 1999). FOXO3a localization has
been utilized to determine whether a cell is in a prosurvival or proapoptotic state
(Jacobs et al., 2003) (Wen et al., 2011). Nuclear FOXO3a suggests that
signaling pathways such as the PI3Kinase/Akt pathway are inactive and FOXO3a
is acting as a proapoptotic transcription factor within the nucleus. Bim and p27
are examples of proteins whose gene expression is upregulated by nuclear
localized FOXO3a. When the PI3Kinase/Akt signaling pathway is activated,
FOXO3a is phosphorylated by Akt and excluded from the nucleus, rendering it
inactive. FOXO3a has been shown to localize to the nucleus in response to
chemotherapeutic drugs, such as Doxorubicin, in a breast cancer cell line (Ho et
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al., 2012). Furthermore, in patient tissue samples, nuclear localization in luminallike breast cancers has been associated with a good prognosis (Habashy et al.,
2011). Direct effects of estrogen receptor stimulation on FOXO3a
phosphorylation have not been investigated.
Previous studies in our lab have demonstrated that stimulation of GPER and ERα
results in the accumulation of the PH-RFP reporter in the nucleus (Revankar et
al., 2005). These studies were performed in COS-7 cells cotransfected with
GPR30-GFP/ERα-GFP and PH-RFP, and nuclear localization of PH-RFP in
response to receptor stimulation was monitored using confocal microscopy. The
PH domain of Akt binds to phosphatidylinositol (3,4,5)-triphosphate (PIP3), which
is generated from the phosphorylation of phosphatidylinositol 4,5-bisphosphate
(PIP2) by the upstream PI3Kinase. PI3Kinase inhibition abolished the nuclear
accumulation of PIP3 in this assay, suggesting that GPER and ERα stimulation
results in the activation of PI3Kinase. Furthermore, our previous studies also
demonstrated that in the human breast cancer cell line SKBR3, which express
GPER and are ERα-/ERβ- negative, estrogen and the GPER specific agonist G-1
were able to stimulate PIP3 production in the nucleus. The mechanism and
downstream effects of estrogen receptor stimulated PI3Kinase activation are not
well understood. In the present study, we utilized the human breast cancer cell
line MCF7, which express all three estrogen receptors (ERα, ERβ and GPER) in
order to provide a more physiologically relevant setting to investigate estrogen
receptor activation of the PI3Kinase pathway.
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2.3. Materials and Methods
Cell Culture
The human breast cancer cell line, MCF7 (ATCC) were maintained in Dulbecco’s
modified eagle’s medium (DMEM) (Sigma) with 1% Penicillin/Streptomycin/
Glutamine Solution (100X) (Thermo Scientific) and 10% Fetal Bovine Serum
(Thermo Scientific). Where serum starvation is indicated, DMEM was replaced
with DMEM/F-12 50/50 without phenol red (Cellgro, Mediatech) with 1%
Penicillin/Streptomycin/Glutamine Solution.
Inhibitors and Antibodies
LY 294002 (LY) (CalBiochem) is used as a broad spectrum inhibitor of all
PI3Kinases. PIK-75 (Chemdea, New Jersey) is used to inhibit the p110α isoform
of the PI3-Kinase catalytic subunit, while TGX-221 (Chemdea, New Jersey)
inhibits the p110β isoform. EGFR inhibitor Tyrphostin AG1478 (Calbiochem) is
used to inhibit the EGFR receptor’s tyrosine kinase activation. Primary
antibodies used were Bim, p27, phospho-Akt and Total Akt (Cell Signaling), ERα
(Santa Cruz Biotechnology, Inc.), and GPER polyclonal antibody against a Cterminal peptide in the human GPER protein previously described (Revankar et
al., 2005).
Transfections/Assays
PH-RFP Translocation
The PIP3 binding domain of Akt fused to mRFP1 (PH-mRFP1) was used to
localize cellular PIP3. MCF7 cells were seeded at ~20,000K cells per well on 12
mm coverslips in a 24 well plate 24 hours prior to transfection. Cells were
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transfected with 0.6 µg of PH-mRFP1 using the Lipofectamine 2000 Transfection
reagent (Invitrogen) following the manufacturer’s protocol. Approximately 24
hours after transfection cells were serum starved for 24 hours followed by
stimulation with ligands as indicated. The cells were fixed with 2% PFA in PBS,
washed, mounted in Vectashield (Vector Laboratories, Inc.) and analyzed by
confocal microscopy on the Leica SP5 microscope. Images were analyzed using
Slidebook. A mask for the nucleus alone and for the entire cell including the
nucleus was created. The average nuclear intensity of the cy3 channel divided
by the average intensity of the entire cell indicates the amount of PH-RFP that is
localized to the nucleus after stimulation.
FoxO3-GFP Translocation
The FoxO3-GFP plasmid was a generous gift from Dr. Marten P. Smidt
(University of Amsterdam) and was generated as described (Jacobs et al., 2003).
MCF7 cells were seeded at ~20,000K cells per well on 12 mm coverslips in a 24
well plate 24 hours prior to transfection. Cells were transfected with 0.6 µg of
FoxO3-GFP using the Lipofectamine 2000 Transfection reagent (Invitrogen)
following the manufacturer’s protocol. Approximately 24 hours after transfection
cells were serum starved for 24 hours followed by stimulation with
ligands/inhibitors as indicated. The cells were fixed with 2% PFA in PBS,
washed, mounted in Vectashield and analyzed by confocal microscopy on the
Leica SP5 microscope. Approximately 50 cells per treated coverslip were
counted through the eyepiece and the localization of FoxO3-GFP was assessed.
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Localization status was separated into three categories: predominantly nuclear,
partially nuclear, and cytoplasmic.
siRNA and FOX3-GFP Translocation
MCF7 cells were seeded at ~20,000K cells per well on 12 mm coverslips in a 24
well plate 24 hours prior to transfection. Small-interfering RNA (siRNA) was from
Dharmacon RNAi Technologies (Lafayette, CO, USA). 50 pmol per well of
siGPER (ONTARGET plus SMARTpool siRNA (L-005563-00)), siERα
(ONTARGET plus SMARTpool siRNA (L-003401-00) Human ESR1), and
siControl (ON-TARGETplus siControl Non-Targeting siRNA (D-001810-02)) were
transfected using Lipofectamine 2000. 24 hours after transfection, 0.6 µg of
FoxO3-GFP was transfected into each well. The next day, cells were serum
starved for 24 hours and treated as specified. The cells were fixed with 2% PFA
in PBS, washed, mounted in Vectashield and analyzed by confocal microscopy
on the Leica SP5 microscope. Approximately 50 cells per treated coverslip were
counted and the localization of FoxO3-GFP was assessed.
Immunofluorescence
Akt Antibody Staining and Localization
MCF7 cells were seeded onto 12 mm coverslips in a 24 well plate, serum starved
for 24 hours, then treated with ligands as indicated. Cells were fixed in 2% PFA,
permeabilized with 0.1% Triton-X100 for 10 minutes, and 1% BSA blocking for 1
hour. Coverslips were then incubated with 1:200 Akt antibody in 1% BSA
overnight in a moist chamber at 4˚C. Cells were then washed with PBS and
incubated with Goat anti-rabbit Alexa 533 secondary antibody for 1 hour at room
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temperature in the dark. After washing with PBS, coverslips were mounted with
Vectashield and analyzed by confocal microscopy. Akt cellular distribution was
analyzed using Slidebook. The nucleus was isolated by masking and the
average nuclear intensity of the Cy3 channel was determined.
Caspase Activation
Magic Red® Caspase 3/7 Detection Kit (Immunochemistry Technologies) was
utilized in order to monitor Capsase 7 activation in MCF7 cells. MCF7 cells were
seeded onto 12 mm coverslips in a 24 well plate. Approximately 24 hours after
seeding, treatments were added for 1, 2, 3 and 5 days. At the end of each time
point, cells were incubated with the Magic Red substrate solution diluted as
directed by manufacturer’s protocol for 1 hour at 37˚C, washed twice with PBS
and fixed with 4% PFA. Cells were washed twice and stained with TO-PRO®-3
(life technologies) for 10 minutes at room temperature in the dark then washed
twice again with PBS. The coverslips were mounted in Vectashield and analyzed
by confocal microscopy on the Leica SP5 microscope.
Western Blotting
MCF7 cells were seeded to 60-80% confluency in 60 mm dishes and serum
starved 24 hours prior to indicated treatments. After treatment, cells were
washed twice with cold PBS and scraped into lysis buffer. Cells were lysed in
RIPA buffer containing NP-40 supplemented with sodium fluoride (50 mM),
sodium orthovanadate (1 mM), phenylmethylsulfonylfluoride (1 mM), 0.1% SDS,
0.5% sodium deoxycholate and protease cocktail (1X). Cell lysate protein
concentration was determined by Bradford protein assay (Bio-Rad, Hercules,

40

CA). Equal protein concentrations per lysate were loaded on a 4-20% Precise
Tris-Glycine Gels (Thermo Scientific) and transferred to polyvinylidene difluoride
membranes (Millipore). Membranes were blocked in 5% Blotting Grade Blocker
Non-Fat Dry Milk (Bio-Rad) for 1 hour at room temperature and then incubated
with primary antibodies (1:1000 dilution for Bim, p27 and pAkt) (1:500 for ERα)
(1:5000 for GPER) (1:10,000 for actin) in 3% BSA overnight at 4˚C with gentle
rocking. After a series of washes, the blots were then incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:3000) or goat anti-mouse IgG for
actin (1:5000) in 3% BSA for 1 hour at room temperature with gentle rocking.
The blots were developed using Supersignal West Pico Chemiluminescent
Substrate (Thermo Fisher). Films were scanned and quantified using ImageJ
software (National Institutes of Health).
Image Analysis
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5. Analysis
was done with a one way analysis of variance (ANOVA) within Prism estimates
the correlation of variables with treatment groups (DMSO, EGF, G-1, E2, etc).
Pairwise comparisons of results between different treatment groups were
determined using a one-way Analysis of Variance (ANOVA) comparing all values
to control followed by a Dunnett’s posttest. Data represents the mean ± SEM of
three or more separate experiments. P-values less than .05 were considered to
be significant. In order to determine significance in siRNA experiments between
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siControl and siGPER or siERα as well as EGF time points, a two way ANOVA
analysis was performed utilizing Bonferroni posttest.

2.3. Results
PH-RFP localization in MCF7 cells.
In order to determine whether estrogen receptor stimulation leads to PI3Kinase
activation, we utilized the PH reporter assay previously described. EGF is
utilized as a positive control because it is known to activate the PI3Kinase
pathway (Burgering and Coffer, 1995). Although EGF induced a small but
significant increase in PH-RFP in the nucleus, there was no detectable difference
in PH-RFP within the nucleus of MCF7 cells upon stimulation with E2 and G-1
compared to DMSO vehicle control (Figure 2.1). There is an observable amount
of PH-RFP within the nucleus under non-treated, starved conditions (Figure
2.1a). This potentially suggests that the difference between residual PIP3
generation and the amount that occurs following estrogen receptor stimulation is
below the detection limit.
Estrogen receptor stimulation induces phosphorylation of Akt in MCF7
cells.
Downstream of PI3Kinase activation, Akt is recruited to PIP3 and phosphorylated
by PDK. Therefore we monitored the phosphorylation of Akt at the Ser473
position in response to estrogen receptor stimulation (Figure 2.2). E2 induces a
slight increase in phospho-Akt compared to DMSO vehicle control. However, the
GPER-selective ligand G-1 significantly enhances the phosphorylation of Akt
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compared to control. This suggests that GPER is the receptor responsible for
Akt activation in response to E2 and that E2’s activation of this pathway via
GPER in MCF7 cells may be counteracted by E2 binding to ERα and ERβ as
well resulting in alternative cellular effects. When cell lysates were preincubated
with the PI3Kinase inhibitor LY 294002 (LY), phosphorylation of Akt by all ligands
was inhibited, suggesting that GPER activation resulting in Akt phosphorylation
requires PI3Kinase.
Estrogen receptor stimulation induces translocation of Akt in MCF7 cells.
We have previously demonstrated PIP3 accumulation in response to E2 and G-1
in the nucleus of COS-7 cells with exogenously expressed estrogen receptors
(Revankar et al., 2005). In order to investigate the downstream effects of this in
cells with endogenous estrogen receptors, we examined whether Akt would
translocate to the nucleus in response to E2 and G-1 in MCF7 cells. MCF7 cells
were treated with DMSO vehicle control, EGF, E2 and G-1, followed by staining
with an Akt antibody (Figure 2.3). The average nuclear intensity per cell was
assessed by masking the nucleus to determine the average fluorescence
intensity within the nucleus. While E2 did not induce a significant increase in the
translocation of Akt to the nucleus compared to control (Figure 3c), EGF and G-1
(Figure 2.3b and 2.3d) treatments led to a significant increase in total Akt within
the nucleus. This suggests that G-1 activation of GPER causes Akt to
translocate to the nucleus. It can be hypothesized that E2 stimulation of GPER
activates the Akt already present within the nucleus or that the response would
potentially increase with time.
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Estrogen receptor activation leads to FOXO3a inactivation.
Akt has many known targets within the nucleus (Datta et al., 1999). In particular,
Akt is known to phosphorylate the proapoptotic transcription factor, FOXO3a.
When FOXO3a is active (i.e. unphosphorylated), it resides within the nucleus
functioning as a transcription factor modulating the expression of proapoptotic
genes. In the presence of growth factor signaling that activates the PI3Kinase
pathway, FOXO3a is phosphorylated by Akt and translocates from the nucleus to
the cytoplasm, where it is subsequently degraded. In order to investigate
estrogen receptor activation of the PI3Kinase pathway, we employed a FoXO3GFP fusion protein obtained from the Smidt laboratory (Jacobs et al., 2003). In
humans, FOXO3a is a member of the FOXO class of forkhead transcription
factors. In mice, FoxO3 is FOXO3a’s orthologue. Human FOXO3a and mouse
FoxO3 share a high sequence homology as well as the same Akt
phosphorylation sites (Jacobs et al., 2003). Therefore, we transfected MCF7
cells with FoxO3-GFP and monitored its localization in response to E2 and G-1 to
determine estrogen receptor activation’s effects on FoxO3-GFP. Serum was
utilized as a positive control because it contains multiple growth factors that can
activate the PI3Kinase pathway which would inactivate FoxO3-GFP. EGF was
also a positive control because EGFR activation is known to lead to PI3Kinase
activation (Burgering and Coffer, 1995). DMSO (vehicle) was the negative
control. Depending on the treatment, we observed FoxO3-GFP’s localization in
three distinct patterns: predominantly nuclear, partially nuclear, and
predominantly cytoplasmic (Figure 2.4a and 2.4b). Predominantly nuclear
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(Figure 2.4a cell on right) refers to cells where nuclear FoxO3-GFP is greater
than cytoplasmic, while partially nuclear (Figure 2.4a cell on left) has greater
cytoplasmic localization, but with a visible amount of FoxO3-GFP in the nucleus.
Predominantly cytoplasmic cells do not have any visible FoxO3-GFP in the
nucleus. The percentage of each localization pattern counted per treatment was
plotted (Figure 2.4c). The majority of DMSO treated cells are predominantly
nuclear, with a very low percentage of cells that have a predominantly
cytoplasmic pattern. A high percentage of the serum and EGF treated cells
exhibited a predominantly cytoplasmic pattern. E2 and G-1 treated cells had a
slightly higher percentage of cells that were predominantly cytoplasmic as
opposed to predominantly nuclear. In order to interpret the data based on
FoxO3-GFP’s inactivation by Akt, the predominantly cytoplasmic fraction of each
treatment was analyzed (Figure 2.5). DMSO has a low percentage of cells with
inactive FoxO3-GFP. The positive controls, serum and EGF induced a
substantial increase in cells where FoxO3-GFP was predominantly cytoplasmic
and essentially inactive. E2 and G-1 had a significant percentage of cells with
predominantly cytoplasmic FoxO3-GFP compared to control suggesting that
estrogen receptor stimulation can inactivate FOXO3a. To determine the
dependence of FoxO3-GFP’s inactivation on concentration, increasing amounts
of E2 and G-1 were added (Figure 2.6). The maximum response for E2 was
obtained at 50 nM, while the maximum response for G-1 was at 100 nM.
Estrogen receptor activation leads to rapid FOXO3a inactivation.
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Since rapid signaling events typically occur within 30 minutes, FoxO3-GFP’s
inactivation by estrogen receptor activation was monitored over a 30 minute
period. The maximum response to E2 and G-1 compared to control was
observed at 15 minutes (Figure 2.7). While a sustained response is still
observed at 30 minutes, this is the first report of rapid inactivation of FOXO3a in
response to estrogen receptor stimulation in a breast cancer cell line.
GPER is the estrogen receptor responsible for inactivation of FoxO3-GFP.
MCF7 cells express three estrogen receptors (GPER, ERα and ERβ), all of which
are capable of binding E2. Because FoxO3-GFP can be inactivated by E2 and
G-1, we next sought to determine which estrogen receptor was responsible for
E2 inactivation of FoxO3-GFP. MCF7 cells were consecutively transfected with
GPER siRNA and FoxO3-GFP, and FoxO3-GFP inactivation in response to E2
and G-1 was assessed. Knockdown of GPER significantly reduced E2 and G-1’s
ability to inactivate FoxO3-GFP (Figure 2.8a) indicated by a significant decrease
in the percentage of cells with cytoplasmic FoxO3-GFP. This suggests that
GPER is the estrogen receptor responsible for E2’s inactivation of FoxO3-GFP.
Furthermore, knockdown of GPER did not affect EGF’s ability to inactivate
FoxO3-GFP (Figure 2.8b). GPER knockdown was confirmed by western blot
(Figure 2.8c).
To further establish GPER’s role in FoxO3-GFP’s inactivation, ERα was knocked
down in MCF7 cells. Utilizing cells transfected with ERα siRNA with FoxO3-GFP
had no effect on E2’s ability to inactivate FoxO3-GFP (Figure 2.9a). EGF was
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also able to inactivate FoxO3-GFP, and ERα knockdown was confirmed by
Western blot (Figure 2.9b and 2.9c).
FOXO3-GFP inactivation requires PI3-Kinase and the transactivation of
EGFR in MCF7 cells.
It has been previously established that GPER stimulation leads to PI3Kinase
activation and that EGFR transactivation was required as an intermediate in this
signaling pathway (Revankar et al., 2005). To confirm PI3Kinase’s role in
GPER’s inactivation of FoxO3-GFP in our current model, MCF7 cells with
FoxO3-GFP were preincubated with the broad spectrum PI3Kinase inhibitor LY
294002 (LY) and subsequently treated with EGF, E2 and G-1 (Figure 2.10a). LY
294002 was able to abrogate FoxO3-GFP’s inactivation by these ligands
establishing that PI3Kinase is required (Figure 2.10a). EGFR is also essential
because the EGFR inhibitor, AG1478 was also capable of significantly reducing
FoxO3-GFP's inactivation by EGF, E2 and G-1 (Figure 2.10a). A representative
image of the predominantly nuclear localization pattern that was observed with
LY 294002 and AG1478 treatments is shown (Figure 2.10b).
The p110α subunit of PI3Kinase is responsible for FoxO3-GFP inactivation
while p110β inhibition enhances p110α activity.
The Class IA subset of PI3Kinases employs PIP2 as their substrate and consists
of a catalytic subunit (p110) and a regulatory subunit (p85). The two ubiquitously
expressed PI3Kinase isoforms, p110α and p110β, have differing functions
(Kumar et al., 2011). In order to determine which PI3Kinase isoform is
responsible for inactivation of FoxO3-GFP as a result of GPER stimulation, cells
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were preincubated with either PIK-75 which inhibits p110α, or the p110β inhibitor,
TGX-221 (Figure 2.11a). PIK-75 inhibited FoxO3-GFP inactivation by EGF, E2
and G-1 suggesting that p110α is the PI3Kinase subunit responsible. TGX-221
surprisingly enhanced FoxO3-GFP inactivation, even when it was added to cells
alone as a control. We hypothesized that there may exist a balance or crossinteraction between the two p110 isoforms such that inhibiting p110β may
increase p110α activity. To test this, we incubated MCF7 cells with FoxO3-GFP
in the presence of both TGX-221 and PIK-75, with the goal that if TGX-221
inhibition of p110β is resulting in the activation of p110α, then this activity should
be inhibited by the p110α-specific inhibitor (Figure 2.11b). Indeed, inhibiting both
p110 catalytic subunits ablated the inactivation of FoxO3-GFP, suggesting that
inhibiting p110β does cause an upregulation in the activity of p110α.
Estrogen receptor stimulation does not significantly affect Bim or p27
levels.
FOXO3a is a transcription factor responsible for the expression of proapoptotic
genes that encode proteins such as Fas ligand, TRAIL, Bim and the cell cycle
inhibitor, p27kip. In order to determine if E2 and/or G-1 stimulation of GPER
leading to inactivation of endogenous FOXO3a can decrease the protein levels of
Bim and p27, MCF7 cells were treated with ligands, lysed and separated by gel
electrophoresis. Western blot analysis of Bim and p27 levels in cells treated with
DMSO, EGF, E2 and G-1 over 24 and 48 hours revealed no significant difference
between samples (Figure 2.12). One possible explanation is that E2 and G-1 are
able to inactivate FOXO3a in approximately 20 percent of the cells, so measuring
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Bim and p27 level changes in whole cell lysates could potentially be difficult to
detect.
E2 and G-1 reduce Caspase 7 activation in MCF7 cells.
It can be hypothesized that E2 and G-1 inactivation of FoxO3-GFP would shift
cells towards a more prosurvival state since FOXO3a is a proapoptotic
transcription factor. Caspase activation is an indicator of the initiation of
apoptosis, which eventually results in cell death. To test this, MCF7 cells were
incubated with DMSO, serum, E2 and G-1 for 1, 2, 3 and 5 days. Before fixing,
cells were then incubated with the Magic Red Caspase substrate for 1 hour. The
Magic Red substrate can be cleaved by activated caspase 3 or 7, generating a
fluorescent product that can be monitored utilizing confocal microscopy. MCF7
cells are caspase 3 deficient, suggesting that the Magic Red substrate would be
cleaved by any activated Caspase 7 (Janicke et al., 1998). After 1 or 2 days,
there is not an observable difference in 10 nM E2 or 100 nM G-1 treated cells
compared to DMSO vehicle control (Figure 2.13a). However at these shorter
time points, 10 nM G-1 and 50 nM E2 displayed an observable decrease in
caspase activation. Prolonged treatments (3 and 5 days) indicate that 10 nM E2,
10 nM G-1 and 50 nM E2 result in decreased caspase activation as compared to
DMSO control (Figure 2.13b). These results suggest that prolonged exposure to
E2 can reduce caspase activation in MCF7 breast cancer cells. Because G-1
can also reduce caspase activation at longer time points, we hypothesize that
GPER is partially responsible for this decrease.
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2.4. Discussion
Several reports have demonstrated in MCF7 cells, the ability of
chemotherapeutic drugs to induce FOXO3a activation (i.e. accumulation of
FOXO3a in the nucleus) (Sunters et al., 2006) (Ho et al., 2012). FOXO3a
activation results in an increase in proapoptotic protein expression and provides
a mechanism for how these drugs can induce apoptosis in breast cancer cells,
specifically MCF7 cells. The steroid hormone estrogen (E2) is known to cause
progression of hormone-sensitive tumors, including breast cancer, through its
classical nuclear receptors by transcriptional regulation resulting in cell
proliferation and survival (Lappano et al., 2014). However, E2 has also been
demonstrated to have rapid signaling growth effects through an additional
receptor, GPER. These signaling effects include the activation of MAPKs as well
as activation of the PI3Kinase pathway (Filardo et al., 2000) (Revankar et al.,
2005). The downstream effects of PI3Kinase activation by E2 have not been
extensively studied. However, it has been established that PI3Kinase activation
by growth factor receptors in general can stimulate AKT to phosphorylate and
inactivate FOXO3a thereby excluding it from the nucleus (Brunet et al., 1999).
Here we provide a mechanism by which the activation of GPER by E2 and the
GPER-selective agonist, G-1, can lead to PI3Kinase/AKT activation and
subsequently the inactivation of FOXO3a.
It was previously established by our lab that activation of GPER by E2 and G-1,
as well as E2 activation of ERα leads to the accumulation of PIP3 in the nucleus
(Revankar et al., 2005). PIP3 nuclear accumulation required PI3Kinase
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activation and the EGFR. This assay was performed in COS-7 cells transiently
expressing these receptors and SKBR3 cells which only express GPER. In order
to investigate this pathway utilizing a more physiologically relevant model of ERαpositive breast cancer, we employed MCF7 cells, which express all three
estrogen receptors (ERα, ERβ and GPER), throughout this study. First, we
sought to determine whether E2 and/or G-1 stimulation of MCF7 cells would
result in the nuclear accumulation of PIP3. MCF7 cells transfected with the PHRFP reporter did not show significant translocation of the PH-RFP reporter
compared to vehicle control (Figure 2.1). Under serum starved conditions in the
presence of the negative control, there is still an observable amount of PH-RFP
in the nucleus (Figure 2.1a). Therefore, one possibility could be that there is a
basal level generation of PIP3 within the nucleus of MCF7s. Because MCF7
cells are a breast cancer cell line, they could potentially have heightened
activation of one or more growth factor pathways which could possibly be the
reason for the basal level of PIP3 within the nucleus. Basal level PIP3 could
make it difficult to detect any significant changes in PIP3 generation within the
nucleus upon estrogen receptor stimulation. Additionally, PH-RFP is
overexpressed and its localization under serum starved conditions may or may
not reflect where PIP3 is actually being generated, again making it difficult to
detect an increase in nuclear PH-RFP localization upon estrogen receptor
stimulation.
To evaluate activation of Akt as a consequence of estrogen receptor activation,
we monitored the total amount of phospho-Akt in MCF7 cells (Figure 2.2). We
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utilized EGF as a positive control since it is known to activate the PI3Kinase/Akt
pathway (Burgering and Coffer, 1995). EGF and G-1 are able to significantly
increase phospho-Akt levels compared to control, while E2 only showed a trend
towards increased phospho-Akt levels. Previous results demonstrate that E2
treatment of MCF7 cells only slightly increased phospho-Akt levels between 0
and 24 hours with a maximum, significant increase at 72 hours (Lee et al., 2005).
Our experiments were performed in 20 minutes to monitor rapid signaling effects;
therefore we might not be able to detect increased phospho-Akt level effects if
they take longer to occur. Furthermore, since E2 binds to all three estrogen
receptors in MCF7s, we propose that knockdown of ERα and ERβ, isolating E2
stimulation of GPER would result in the same significant rapid increase of
phospho-Akt levels as G-1 in MCF7 cells because it is possible that ERα and
ERβ are potentially counteracting E2’s effects as a result of GPER stimulation.
An additional experiment would be to measure phospho-Akt levels with E2 and
G-1 treatment over a 24 hour time period to determine if the rapid
phosphorylation of Akt by GPER would be sustained.
Previous results from our lab have suggested nuclear signaling in response to
estrogen receptor stimulation by nuclear pip3 accumulation (Revankar et al.,
2005). Other results observed in endometrial cancer cells suggest Akt activation
within the nucleus as an outcome of estrogen stimulation (Abe et al., 2011). In
this particular study they monitored phospho-Akt and total Akt levels within the
nucleus of endometrial cancer cells overexpressing ERα. A significant difference
in both phospho-Akt and total Akt nuclear levels was reported following 1 to 3
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hours of E2 treatment. They also correlated poor prognosis to nuclear phosphoAkt. In the current study we are able to demonstrate rapid translocation (15
minutes) of total Akt in response to EGF and G-1, but no significant difference in
E2-mediated translocation of total Akt at this time point (Figure 2.3). This
suggests that GPER is responsible for rapid translocation of Akt in MCF7 cells.
Based on the previously published results in endometrial cancer cells, longer
time points might be necessary to determine E2’s effects on total Akt
translocation in MCF7 cells.
Downstream of its translocation and activation, Akt has specific kinase functions
within the nucleus that regulate cell survival (Datta et al., 1999). One wellestablished function is the phosphorylation of FOXO3a, resulting in its
inactivation and subsequent exclusion from the nucleus (Brunet et al., 1999).
Others have utilized the shuttling mechanism of FOXO3a inactivation by
transfecting a GFP-construct into PC12 cells and monitoring FoxO3-GFP
localization in response to NGF (Wen et al., 2011). Because we were able to
detect rapid activation of phospho-Akt and translocation of total Akt to the
nucleus in MCF7 cells, we sought to elucidate the downstream effects of this by
monitoring FOXO3a inactivation. FoxO3-GFP, a mouse orthologue construct
with sequence homology to human FOXO3a, was transfected into MCF7 cells.
FoxO3-GFP’s localization after treatments was assessed by microscopy and
separated into three categories, ranging from predominantly nuclear to
predominantly cytoplasmic (Figure 2.4). Ultimately, the extent of cytoplasmic
localization was used as an indicator of FoxO3-GFP inactivation (Figure 2.5).
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We observed that not only did E2 inactivate FoxO3-GFP significantly as
compared to control, but so did the GPER-selective agonist G-1. It is not clear
whether the partially nuclear state indicates the cell is in a more proapoptotic or
prosurvival state. Further studies to assess this may include microscopy
analysis, on a cell to cell basis, of the downstream product of FOXO3a, Bim. Bim
levels would be an indicator of FOXO3a’s activity and we predict that there would
be a detectable decrease in cells with cytoplasmic FoxO3-GFP and potentially
partially nuclear cells compared to predominantly nuclear cells (Kim et al., 2014).
Furthermore, we were able to determine that inactivation of FoxO3-GFP is
dependent on concentration as well as time (Figures 2.6 and 2.7). The maximum
response for E2 was 50 nM and 100 nM for G-1 at 15 minutes. 10 nM E2 and 10
nM G-1 also significantly increased FoxO3-GFP inactivation but the effect was
beginning to decrease by 300 nM. Higher doses of G-1 have been reported to
exhibit antiproliferative effects in MCF7 cells which could potentially explain the
decrease in inactivation of FOXO3a at high doses of E2 and G-1 (Ariazi et al.,
2010).
GPER is known to be responsible for at least some of the rapid signaling effects
of E2 (Filardo et al., 2000) (Revankar et al., 2005). Because the GPER selective
agonist G-1 had a significant effect on phospho-Akt levels and the translocation
of Akt to the nucleus, we hypothesized that GPER was also responsible for the
inactivation of FoxO3-GFP in response to E2. Knockdown of GPER significantly
decreased FoxO3-GFP inactivation compared to siControl (Figure 2.8).
However, knockdown of ERα had no significant effect (Figure 2.9). It was
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recently published that FoxO3a overexpression decreases motility, invasiveness,
and anchorage-independent growth in MCF7 cells and that this is dependent on
ERα expression (Sisci et al., 2013). Here it was suggested that E2 treatment of
MCF7 cells allowed for a synergistic activation of FOXO3a, dependent on ERα
and leading to Caveolin-1 expression, which was suggested to decrease
invasiveness and migration. There was no account for GPER’s effect in this
study. E2 binds GPER in MCF7 cells as well so there is likely a balance between
the two receptor pathways. We propose that knockdown of endogenous ERα
would reverse this effect because E2 stimulation of GPER in MCF7 cells would
inactivate FOXO3a and exclude it from the nucleus, decreasing Caveolin-1
expression. We did not determine a role for ERβ in these studies; however ERα
and ERβ have been reported to interact with FOXO3a in MCF7 cells (Zou et al.,
2008). This raises the possibility that if ERα and ERβ interact with FOXO3a and
potentially keep it localized to the nucleus, this could result in constitutive
FOXO3a activity and proapoptotic effects.
To delineate the pathway by which E2 and G-1 inactivate FoxO3-GFP in MCF7
cells we employed inhibitors and monitored their effects on FoxO3-GFP
inactivation (Figure 2.10a). As expected, the PI3Kinase inhibitor, LY 294002,
blocked FoxO3-GFP inactivation by EGF, E2 and G-1, which is evidenced by the
strong nuclear localization of FOXO3-GFP in cells treated with LY 294002
(Figure 2.10a and 2.10b). It has been previously determined that PI3Kinase can
activate Akt in MCF7 cells and that this effect is inhibited by LY 294002 (Jordan
et al., 2004). It has also been reported that the p85 subunit of PI3Kinase can
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interact with ERα in the presence of estrogen and that this interaction mediates
protection from apoptosis in MCF7 cells (Greger et al., 2007). Additionally, the
p110α subunit of Class IA PI3Kinases has a known mutation in its gene that
results in constitutive activation and that is found to be mutated in 35% of breast
cancers (Janku et al., 2014) (Polivka and Janku, 2014). Here we provide the first
report that implicates the p110α subunit of PI3Kinase is responsible for GPERmediated inactivation of FOXO3a (Figure 2.11a). The p110β subunit has been
described to have a nuclear localization and has also been deemed to be
involved in certain nuclear processes, including DNA replication and repair
(Marques et al., 2009) (Kumar et al., 2010) (Kumar et al., 2011). Our results
indicated that the p110β subunit PI3Kinase is not responsible for EGF, E2, or G1 induced inactivation of FOXO3a (Figure 2.11a). Furthermore, inhibition of
p110β actually enhances p110α activity in MCF7 cells (Figure 2.11b). One
possible explanation for the enhanced p110α activity as a result of p110β
inhibition could be that activated p110β can associate with a fraction of activated
p110α sequestering it from its substrates. Therefore, when p110β is inhibited
and can potentially no longer interact with this fraction of p110α, p110α is no
longer associated with p110β which results in its increased activity.
Generally, GPCRs are known to transactivate the EGFR through a signaling
cascade involving the activation of Src which results in the activation of
membrane-bound MMPs such as the ADAM family members (George et al.,
2013). These MMPs can cleave EGF ligands that in turn bind to the EGFR and
other EGFR family members and promote dimerization and activation of these
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receptors. It was first demonstrated in 2000, that estrogen transactivates the
EGFR to the MAPK signaling axis via GPER (Filardo et al., 2000). This was
found to occur through the release of surface-bound proHB-EGF in SKBR3 cells,
which are an ER-negative human breast cancer cell line. The transactivation of
EGFR by GPER is mediated by Gβγ-subunit/Src family kinase-dependent
intracellular signals (Filardo, 2002). Later, the Prossnitz laboratory reported in
2005 that PI3Kinase activation of GPER required EGFR (Revankar et al., 2005).
Additionally, in ovarian cancer cells transiently expressing GPER, the activation
of the EGFR and Akt could be significantly enhanced by G-1 and inhibited by a
Src family kinase inhibitor (Fujiwara et al., 2012). This study also correlated poor
outcome with GPER and EGFR expression in ovarian cancer. Here we conclude
that E2 and G-1 inactivation of FoxO3-GFP requires the EGFR (Figure 2.10a).
To further outline EGFR’s mechanism in this pathway, we would need to
investigate whether HB-EGF is cleaved as a result of GPER activation, also
whether Src activation is required.
FOXO3a is a transcription factor which regulates the expression of proapoptotic
proteins. The Bcl-2 proapoptotic family member, Bcl-2 interacting mediator of
cell death (Bim), contains a BH3 domain, allowing it to bind pro-survival Bcl-2
molecules, neutralizing their function. Bim’s association with the PI3Kinase/Akt
pathway was originally investigated in lymphocytes where inhibition of PI3Kinase
by LY 294002 elevated Bim levels (Dijkers et al., 2000). An inducible FOXO3a
construct was utilized and Bim levels were monitored upon induction. In the
presence of prosurvival signals, increasing FOXO3a expression was able to
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elevate Bim. Bim levels were also found to be regulated by FOXO3a in
sympathetic neurons, with higher Bim resulting in apoptosis (Gilley et al., 2003).
FOXO3a can also mediate G1 cell cycle arrest by upregulating expression of the
cell cycle inhibitor p27kip1 (p27) (Medema et al., 2000). p27 blocks the activity
of the cyclin E-cyclin-dependent kinase 2 (CDK2) complex and this prevents cell
cycle progression. There are FOXO binding sites within the p27 promoter, which
suggests that it is directly regulated by activated FOXO3a. Trotman et al. were
able to demonstrate that Pml nuclear bodies can promote apoptosis in prostate
cancer cells by inactivation of nuclear Akt, which renders FOXO3a active and
results in the production of proapoptotic proteins p27 and Bim (Trotman et al.,
2006). Since it has been established that FOXO3a can directly regulate Bim and
p27 expression levels, we sought to determine whether E2 and G-1 inactivation
of FOXO3a would decrease Bim and p27 levels in MCF7 cells (Figure 2.12).
When analyzing the data, it appears that G-1 is trending towards a reduction of
Bim after 48 hours. Otherwise, no significant difference in Bim protein levels was
detected. Additionally, it appears that p27 levels were trending towards a
decrease when treated with E2 after 48 hours. We hypothesize that detecting
Bim and p27 level changes in a whole cell population may mask the effect of
FOXO3a inactivation by GPER stimulation that we are able to observe on the
single cell level. A potential reason for not being able to detect a significant
decrease in Bim and p27 protein levels is that only approximately 20 percent of
the cells treated exhibited a predominantly cytoplasmic pattern of FoXO3-GFP.
A decrease in protein levels as a result of this inactivation may be too difficult to
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detect in a whole cell population over this time period. Additionally, since our
positive control, EGF was not able to induce a decrease in Bim or p27 levels, it is
possible that serum starvation prior to treatment pushed the cells to a
proapoptotic state that was not able to be reversed by EGF, E2 or G-1 treatment.
The long term effects on Bim and p27 levels in the presence of E2 and G-1
should be further examined to determine whether there is a decrease over time
with extended exposure to estrogen receptor ligands.
Although we were not able to observe a detectable decrease in the proapoptotic
protein levels of Bim and p27, we still sought to determine whether E2 and G-1
inactivation of FOXO3a could result in decreased apoptosis of MCF7 cells. In
order to investigate this on a cellular level, a cleavable fluorescent substrate was
incubated with MCF7 cells after 1, 2, 3 and 5 days of treatment. It can be
concluded that prolonged exposure to E2 results in an observable decrease in
caspase activation (Figure 2.13b). A lower concentration of G-1, but not E2 is
able to decrease caspase activation at earlier time points (Figure 2.13a). We
hypothesize that this is a result of rapid signaling effects of GPER stimulation that
are still observed after 3 and 5 days. We also predict that based on our results,
inactivation of FOXO3a is partially responsible for decreased caspase activation.
Further experiments to delineate FOXO3a’s role in decreased caspase activation
in MCF7 cells are required.
There are conflicting studies regarding the prognosis of breast cancer tissue
samples with nuclear localized FOXO3a (Chen et al., 2010) (Habashy et al.,
2011). Our results demonstrating FOXO3a inactivation and nuclear exclusion by
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E2 and G-1 suggest this is one possible mechanism by which tumor cells evade
apoptosis. Therefore we hypothesize, that in a tumor environment, nuclear
FOXO3a would be more beneficial because it would shift the cells towards a
more proapoptotic state.

60

Figure 2.1
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Figure 2.1. PH-RFP localization in MCF7 cells. (a-d) MCF7 cells were
transfected with PH-mRFP1 and serum starved for 24 hours prior to treatments.
Cells were treated with 0.1% DMSO, 50 ng/ml EGF, 50 nM E2 and 100 nM G-1
for 15 min. (e) Images were analyzed with Slidebook by creating a nuclear mask
and a mask of the whole cell. Each cell’s nuclear mean intensity was divided by
its total cell mean intensity and was plotted as a data point. [Relative to control
(DMSO) p = <.05 for EGF (*)].
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Figure 2.2. Estrogen receptor stimulation induces phosphorylation of Akt in
MCF7 cells. MCF7 cells were serum starved for 24 hours prior to treatments.
Cells were treated with 0.1% DMSO, 50 ng/ml EGF, 50 nM E2 and 100 nM G-1
for 20 min. Where indicated cells were pretreated with 10 μM LY 294002 (PI3Kinase inhibitor) for 30 min. Cells were lysed in RIPA buffer, separated by gel
electrophoresis, transferred by Western blot and quantitated using ImageJ
software. Results were analyzed using a one way ANOVA with Dunnett's Multiple
Comparison post hoc test. [Relative to control (DMSO) p = <.05 for EGF and G-1
(*). Relative to ligand without inhibitor (#) p = <.01 for E2 and G-1(**), p = <.05
for EGF (*)].
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e.)

Figure 2.3. GPER stimulation induces nuclear translocation of Akt in MCF7
cells. (a-d) MCF7 cells were serum starved for 24 hours prior to treatments.
Cells were treated with 0.1% DMSO, 50 ng/ml EGF, 50 nM E2 and 100 nM G-1
for 15 min. (e) Images were analyzed with Slidebook by creating a nuclear mask
in order to measure the mean intensity of that area. Each cell’s nuclear mean
intensity was plotted as a data point. [Relative to control (DMSO) p = <.001 for
EGF and G-1 (***)].
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Figure 2.4. FoxO3-GFP localization. (a) MCF7 cells transfected with FoxO3GFP and supplemented with serum free media for 24 hr. (b) MCF7, same as Fig
2a., treated with 50ng/ml EGF for 15 min. (c) Cells were treated with 0.1%
DMSO, 0.1% DMSO and serum, 50ng/ml EGF, 50nM E2 and 100nM G-1 for
15min. Based on the images in (a) and (b) cells were separated into the indicated
categories and approximately 50 cells were counted per treatment.
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f.)

Figure 2.5. Estrogen receptor activation leads to FOXO3a inactivation.
MCF7 cells transfected with FoxO3-GFP were serum starved for 24 hours and
treated as indicated in Figure 4c for 15 min. (a-e) Representative images. f.)
Results were analyzed using a one way ANOVA with Dunnett's Multiple
Comparison post hoc test. [Relative to control (DMSO) p = <.001 for serum, EGF
(***), p = <.01 for E2 (**), p = <.05 for G-1 (*)].
68

Figure 2.6. Estrogen receptor inactivation of FOXO3a is concentration
dependent. MCF7 cells transfected with FoxO3-GFP were serum starved for 24
hours and treated as indicated with E2 and G-1. Results were analyzed using a
one way ANOVA with Dunnett's Multiple Comparison post hoc test. [Relative to
control (DMSO) at each concentration p = <.01 for 50 nM E2 and 100 nM G-1
(**), p = <.05 for 10 nM E2, 10nM G-1 and 300 nM G-1 (*)].
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Figure 2.7. Estrogen receptor activation leads to rapid FOXO3a inactivation.
MCF7 cells transfected with FoxO3-GFP were serum starved for 24 hours and
treated with 0.1% DMSO, 50 nM E2,100 nM G-1 or 50 ng/ml EGF for 5, 15 and
30 min. Results were analyzed using a one way ANOVA with Dunnett's Multiple
Comparison post hoc test. [Relative to control (DMSO) at each time point p =
<.001 for EGF (***), p = <.01 for G-1 (**), p = <.05 for E2, G-1 and EGF (*)].
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a.)

c.)

b.)

Figure 2.8. GPER is required for E2 and G-1 mediated inactivation of
FoxO3-GFP. MCF7 cells were transfected with siGPER and FoxO3-GFP then
serum starved for 24 hours prior to treatments. a.) Cells were treated with 0.1%
DMSO, 50 nM E2 and 100 nM G-1 for 15 min. b.) Cells were treated with 0.1%
DMSO and 50 ng/ml EGF for 15 minutes. c.) Representative Western blot of cell
lysates that were collected at the same time as a.) and b.) treatments. a.) and b.)
Results were analyzed using a one way ANOVA with Dunnett's Multiple
Comparison post hoc test. [Relative to control (DMSO) p = <.001 for EGF (***), p
= <.01 for siControl E2 (**), p = <.05 for siControl G-1 (*)]. siGPER and siControl
were analyzed using a two way ANOVA with Bonferroni post hoc tests. [Relative
to siControl (#) p =<.01 for siGPER E2 (**), p = <.05 for siGPER G-1 (*)].
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a.)

b.)

c.)

Figure 2.9. FoxO3-GFP inactivation does not require ERα. MCF7 cells were
transfected with siERα and FoxO3-GFP then serum starved for 24 hours prior to
treatments. a.) Cells were treated with 0.1% DMSO, 50 nM E2 and 100 nM G-1
for 15 min. b.) Cells were treated with 0.1% DMSO and 50 ng/ml EGF for 15
minutes. c.) Representative Western blot of cell lysates that were collected at the
same time as a.) and b.) treatments. a.) and b.) Results were analyzed using a
one way ANOVA with Dunnett's Multiple Comparison post hoc test. [Relative to
control (DMSO) p = <.001 for siERα E2, siERα G-1, EGF (***), p = <.05 for
siControl E2, siControl G-1 (*)].
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a.)
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b.)

Figure 2.10. FOXO3-GFP inactivation requires PI3-Kinase and the
transactivation of EGFR in MCF7 cells. a.) MCF7 cells were serum starved for
24 hours prior to treatments. Cells were treated with 50 ng/ml EGF, 50 nM E2
and 100 nM G-1 for 15min. Where indicated cells were pretreated with 10 μM LY
294002 (PI3-Kinase inhibitor), 250 nM AG1478 (EGFR inhibitor) for 30 min.
Results were analyzed using a one way ANOVA with Dunnett's Multiple
Comparison post hoc test. [Relative to control (DMSO) p = <.001 (***), p = <.01
(**), p = <.05 (*), Relative to ligand without inhibitor (#)]. b.) Representative image
of MCF7 cells treated with 10 μM LY 294002.
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a.)
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b.)

Figure 2.11. The p110α subunit of PI3Kinase is responsible for FoxO3-GFP
inactivation while p110β inhibition enhances p110α activity. a.) MCF7 cells
were serum starved for 24 hours prior to treatments. Cells were treated with 50
ng/ml EGF, 50 nM E2 and 100 nM G-1 for 15 min. Where indicated cells were
pretreated with 100 nM PIK-75 (p110α inhibitor) and 100 nM TGX-221 (p110β
inhibitor) for 30 min. Results were analyzed using a one way ANOVA with
Dunnett's Multiple Comparison post hoc test. [Relative to control (DMSO) p =
<.001 (***), p = <.01 (**), p = <.05 (*), Relative to ligand without inhibitor (#)]. b.)
MCF7 cells were serum starved for 24 hours prior to treatments. Cells were
treated with 100 nM PIK-75 (p110α inhibitor) and 100 nM TGX-221 (p110β
inhibitor) for 45 min. Results were analyzed using a one way ANOVA with
Dunnett's Multiple Comparison post hoc test. [Relative to control (DMSO) p =
<.05 (*), # = TGX-221 vs. PIK/TGX].
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Figure 2.12. Estrogen receptor stimulation does not significantly affect Bim
or p27 levels. MCF7 cells were serum starved for 24 hours prior to treatments.
Cells were treated with 0.1% DMSO, 50 ng/ml EGF, 50 nM E2 and 100 nM G-1
for indicated times. Cells were lysed in RIPA buffer, separated by gel
electrophoresis, transferred by Western blot and quantitated using ImageJ
software.

77

a.)

2 days

1 day

DMSO

Serum

10 nM E2

10 nM G-1

78

1 day

2 days

50 nM E2

100 nM G-1

79

b.)

5 days

3 days

DMSO

Serum

10 nM E2

10 nM G-1

80

3 days

5 days

50 nM E2

100 nM G-1

Figure 2.13. Estrogen receptor stimulation and caspase activation. MCF7
cells were treated as indicated for 1 and 2 (a), 3 and 5 (b) days. After treatment,
cells were incubated with Magic Red caspase substrate solution for 1 hour at
37˚C. Images are representative of each treatment at each time point.
Accumulation of the cresyl violet fluorescent product is indicative of caspase
activation.
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CHAPTER 3

3. Conclusions, significance and future directions
3.1. Conclusions
The current studies sought to elucidate the mechanism by which PI3Kinase
activation by the G-protein coupled estrogen receptor, GPER, can lead to
prosurvival effects that allow breast cancer cells to evade apoptosis. Since our
previous study in 2005, the literature investigating PI3Kinase and GPER in a
breast cancer cell environment is scarce. Traditionally, PI3Kinase converts the
membrane phospholipid PIP2 to PIP3 at the cytoplasmic plasma membrane
(Czech, 2000). Our results indicating that PIP3 is generated in the nucleus upon
estrogen receptor stimulation was a novel concept and the mechanism by which
this occurs is still unknown. Here, I sought to elucidate this mechanism in MCF7
cells, a breast cancer cell environment that includes all three estrogen receptors,
to provide a more physiologically relevant setting of a typical ER+ breast cancer
cell.
The first approach to understanding this pathway was to transfect the PH-RFP
reporter into MCF7 cells to monitor nuclear PIP3 generation in response to
estrogen receptor stimulation. We were not able to detect a consistent, overall
difference in the amount of PH-RFP that translocates to the nucleus in response
to E2 and G-1 compared to DMSO vehicle control (Figure 2.1). However, there
is an observable amount in the nucleus, even under serum starved conditions
(Figure 2.1a). Nuclear PH-RFP under starved conditions could be the result of
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residual activation of signaling pathways that activate PI3Kinase. There could
also be competition between endogenous proteins and the PH reporter, which
would make any response to stimulus difficult to detect (Czech, 2000).
Additionally, because we transfected MCF7 cells with the PH-RFP reporter, its
localization prior to stimulation may not be indicative solely of PIP3 localization.
Therefore, when the cells are stimulated with ligand, the PH-RFP that is already
localized to the nucleus may bind to PIP3 generated there, masking a
translocation effect. This is in contrast to what we previously observed with
SKBR3 cells, where under unstimulated conditions the PH-RFP reporter is
localized to the plasma membrane due to constitutive EGFR activation from
overexpressed Her2. In order to eliminate any possible expression level
localization effects, we treated cells and then stained them using a PIP3 antibody
(Echelon) to detect endogenous PIP3 generation. The antibody exhibited a
strong nuclear localization even under serum starvation conditions (data not
shown). Previous results were published that describe E2 treatment of MCF7
cells leading to accumulation of the PIP3 antibody at the plasma membrane (Lee
et al., 2005). However, they did not permeabilize the cells and in our
experiments we used 0.1% Triton-X to permeabilize before blocking. Initially, we
blocked and then incubated the cells with the PIP3 antibody without
permeabilization, but saw a more punctate, nonspecific pattern. Because of our
conflicting results with this previously published work, the methods for this
experiment should be further investigated.
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PIP3 is able to bind the PH domain of Akt, which anchors Akt to the membrane
resulting in phosphorylation and activation by PDK. GPER stimulation in MCF7
cells by G-1 was able to induce rapid phosphorylation of Akt (Figure 2.2). We
attribute E2’s slight increase in Akt activation compared to control to GPER
stimulation and propose longer time points based on previous results to show a
more significant increase of phospho-Akt in response to E2 (Lee et al., 2005).
ERα’s contribution to Akt activation in MCF7 cells needs to be determined. We
also examined phospho-Akt on a cellular level by immunofluorescence and
microscopy, but endogenous phospho-Akt levels were more difficult to detect.
One possible way to enhance visualization of phospho-akt levels on a cell to cell
basis, would be to utilize a biotinylated anti-streptavidin antibody. Consecutive
steps result in binding of more fluorochromes at the target site, thereby
amplifying the signal that results from phospho-Akt generated upon estrogen
receptor stimulation in each cell. Phospho-akt detection on a cellular basis would
also delineate Akt localization upon activation.
Akt functions in the cytoplasm as well as the nucleus. Because we hypothesize
that GPER downstream signaling events occur in the nucleus, total Akt
translocation was monitored in response to E2 and G-1. G-1 was able to
significantly induce translocation of Akt to the nucleus compared to control
(Figure 2.3d and 2.3e). No detectable increase in nuclear Akt was observed with
E2, but we hypothesize that since E2 is binding to all three estrogen receptors, it
is likely that Akt’s response is diminished due to competing effects. Also, as we
observed with Akt activation, E2 may not induce rapid translocation of Akt.
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The proapoptotic transcription factor, FOXO3a, is a known nuclear target of Akt
(Brunet et al., 1999). In the presence of growth factor signals, Akt is activated
and phosphorylates FOXO3a. FOXO3a phosphorylation results in its inactivation
and exclusion from the nucleus. We utilized a FoXO3-GFP construct to monitor
its rapid inactivation and translocation from the nucleus to the cytoplasm as a
result of E2 and G-1 treatment. Serum and EGF were positive controls initially,
but EGF was chosen to be the positive control in all subsequent experiments
because it is presumably only acting through the EGFR. Serum contains many
different growth factors such as insulin, which would not allow us to isolate the
signaling effects of the EGFR pathway in order to compare it to the
transactivation of the EGFR by E2 and G-1 GPER stimulation. Compared to the
vehicle DMSO negative control, E2 and G-1 significantly inactivated FoxO3-GFP
(Figure 2.5). This inactivation is concentration dependent and occurs rapidly (in
15 minutes) (Figure 2.6 and 2.7).
Because MCF7 cells express all three estrogen receptors, G-1 is an important
tool in delineating GPER’s role in this pathway. It is also essential to determine
which receptor is mediating E2’s effects. Knockdown of GPER significantly
decreased E2’s ability to inactivate FoxO3-GFP, while ERα knockdown had no
effect (Figure 2.8 and 2.9). These results are the first to demonstrate that GPER
is the estrogen receptor responsible for E2 inactivation of FOXO3a. Zou et al.
reported that FOXO3a functions as a negative regulator of ERα and ERβ by
directly associating with the receptor (Zou et al., 2008). This binding decreases
the transcription of ER related genes and has antiproliferative outcomes. Sisci et
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al. described that overexpression of FOXO3a has antiproliferative effects and
that these effects are dependent on ERα and E2 (Sisci et al., 2013). Neither of
these studies examined GPER’s contribution. Based on our results, if E2
promotes FOXO3a’s apoptotic effects through ERα, then it is possible that
inhibiting E2 binding to GPER could enhance this effect.
p110α is the PI3Kinase catalytic subunit responsible for E2 and G-1 inactivation
of FoxO3-GFP (Figure 2.11a); EGFR is required for this activity (Figure 2.10a).
This is the first report that links the activation of a specific PI3Kinase isoform to
GPER stimulation leading to prosurvival effects in breast cancer cells. GPER’s
involvement in this pathway makes it an attractive target for antagonists such as
G36 and G15 in breast cancers where GPER expression is confirmed and/or
overexpressed.
FOXO3a is a proapoptotic transcription factor that has been described to
regulate the transcription of Bim, p27, Fas Ligand and TRAIL. We attempted to
correlate FOXO3a inactivation by GPER with a change in Bim and p27 proteins
expression levels. A significant decrease over 24 and 48 hours was not
detectable with EGF, E2 or G-1 compared to DMSO vehicle control (Figure 2.12).
MCF7 cells were serum starved for 24 hours before treatments. An alternative
approach might be not to serum-starve the cells and add treatments 24 hours
after cells are seeded. This could potentially decrease the high levels of Bim we
observe at the 24 hour time point, since the cells could already be shifted too far
towards a proapoptotic state that cannot be rescued even by our positive control
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EGF. Then, we anticipate that we may see more detectable differences at the 48
hour time point.
Caspase activation is an important step in the initiation of apoptosis. We
hypothesized that GPER stimulation resulting in the inactivation of FOXO3a
would decrease caspase activation in MCF7 cells. Employing the Magic Red
caspase activation kit, we were able to observe a decrease in caspase activation
with E2 and G-1 compared to DMSO vehicle control at multiple time points
following serum starvation (Figure 2.13). In order to determine if FOXO3a
inactivation is responsible for this decrease in caspase activation, we will utilize a
phospho-FOXO3a antibody. We would predict that since E2 and G-1 treatment
result in a decrease in caspase activation, that there would be a concomitant
increase in phospho-FOXO3a in the cytoplasm.
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3.2. Significance
The rapid signaling effects of estrogen were observed in cells in the mid-1970s,
even before its genomic effects had been characterized (Pietras and Szego,
1975). It wasn’t until 2000 that some of these effects were attributed to the novel
G-protein coupled estrogen receptor (GPR30), which is now termed GPER
(Filardo et al., 2000). In 2005, our group provided evidence for PI3Kinase
activation via GPER (Revankar et al., 2005). Stimulation of GPER has been
shown to activate proliferative/prosurvival pathways that eventually result in
changes in gene expression. Although these pathways are utilized by other
receptors such as the EGFR, and have been characterized, the rapid signaling
effects that occur immediately after GPER stimulation by estrogen and the
components involved are still being characterized.
Estrogen and its canonical receptors are responsible for the growth of hormoneresponsive breast cancer tumors. Targeting these receptors in order to inhibit
their actions has been a major goal of breast cancer treatment. Selective
estrogen receptor modulators (SERMs) were developed for this purpose and
have been widely used. The SERM tamoxifen is an estrogen receptor (ER)
antagonist used to treat ER-positive breast cancers. In a recent study, the
efficacy of tamoxifen treatment in ER-positive breast cancers was analyzed and
results show that recurrence rates after 5 years of tamoxifen treatment were
reduced substantially compared to non-adjuvant treatment over a ten year period
(Early Breast Cancer Trialists' Collaborative et al., 2011). However, tamoxifen
treatment of ER-negative tumors had little or no effect on recurrence rates. More
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recently, another SERM, raloxifene, was developed to decrease the unwanted
toxicity side effects of tamoxifen. In the STAR (Study of Tamoxifen and
Raloxifene) study, although raloxifene had fewer side effects, it did not appear to
be as effective as tamoxifen in reducing the incidence of noninvasive breast
cancer. The raloxifene-treated group from this study also had a nonsignificant
reduction in endometrial cancer. Aromatase Inhibitors (AIs), which inhibit the
aromatase enzyme responsible for the biosynthesis of estrogen, are an
alternative strategy to SERMs. It has been shown that aromatase inhibitors are
highly effective in preventing invasive ER-positive breast tumors in high-risk
women. However, significant side-effects have been observed in follow-up
studies (den Hollander et al., 2013). The side effects of these drugs, as well as
the difficulties in treating ER-negative tumors, suggest that other targets need to
be elucidated in order to more effectively and safely treat breast cancer.
Estrogen has been demonstrated to have rapid signaling effects in breast cancer
cells, such as the activation of adenyl cyclase (AC) resulting in cAMP production
as well as MAP-Kinase activation (Aronica et al., 1994) (Improta-Brears et al.,
1999). In 2000, the antiestrogen ICI 182,780, which can antagonize these
effects in certain ER-positive cells, was discovered to increase MAP-Kinase
activation in MCF7 cells, which are ER-positive, and the ER-negative cell line
SKBR3 (Filardo et al., 2000). This suggested that mitogen activated protein
kinase (MAPK) activation and other rapid signaling effects of E2 could potentially
occur through a non-ER dependent mechanism. This work concluded that
GPER was responsible for the rapid signaling effects of E2 and ICI 182,780 and
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that this signaling required the transactivation of the EGFR. Therefore, GPER
was proposed to be responsible for the lack of effectiveness of antiestrogen
treatments in some ER-negative breast cancers.
Because long-term treatment with tamoxifen was associated with an increased
risk of endometrial cancer, the mechanism for this agonistic effect of tamoxifen
was investigated (Vivacqua et al., 2006). MAPK activation by GPER was
described in endometrial cancer cells and these cells were found to have a
downstream proliferative response to the active metabolite of tamoxifen, 4hydroxytamoxifen (OHT), by upregulating c-fos gene expression. c-fos is a
proto-oncogene that expresses a protein which can heterodimerize with c-jun
and together function as the activating protein 1 (AP1) transcription factor for
regulating proliferative gene expression. This suggests that GPER may be
involved in tamoxifen’s induction of endometrial cancers and that GPER
expression should be considered a factor when determining the most effective
endocrine therapy treatments.
GPER has been suggested to be responsible for tamoxifen resistance, the ability
of tamoxifen to cause proliferative signaling in endometrial cancer cells, as well
as the proliferative signaling in response to the ER antagonist, ICI 182,780.
There are other explanations that have been offered to account for
nonresponsiveness to endocrine therapy: intratumoral heterogeneity in ER
expression, drug resistance as a result of evolution of mutant ERs with reduced
affinity for ER antagonists, partial receptor antagonism, and the presence or
absence of trans-acting factors that influence ER functionality (Filardo et al.,
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2006). Because of these possibilities, more strategies have been employed to
determine ER activity and develop more effective antagonists. One example of a
more complete ER antagonist, fulvestrant, is being assessed in clinical trials for
patients with primary and advanced breast cancer (Ciruelos et al., 2014).
Additionally, progesterone receptor (PR) has become a comarker because its
gene transcription is regulated by ER-dependent gene transactivation, meaning
that if there is high PR expression then there would be an improved response to
tamoxifen. Additionally, a study was performed to acquire baseline information
regarding the potential role of GPER as an independent factor in human breast
cancer (Filardo et al., 2006). The aim of this study was to determine the relative
tissue distribution of GPER, ER and PR in intraductal and invasive ductal
carcinoma. GPER expression varied in breast tumors, in which 62% of invasive
tumors and 42% of intraductal tumors were positive. Codistribution of ER and
GPER was detected in 43% of invasive breast tumors, which indicated a
significant association between ER and GPER. Coexpression of GPER and ER
was linked to PR positivity. Additionally, GPER positively correlated with HER2/neu, tumor size, and metastasis. These results provide further evidence that
GPER has an independent influence on breast cancer and should be utilized as
a marker for treatment and prognosis.
Taxanes, such as paclitaxel and its derivatives, are an alternative class of drugs
utilized in the treatment of breast cancer (Blagosklonny and Fojo, 1999). These
drugs interact with cellular microtubules associated with the spindle apparatus
during mitosis. The taxanes cause cell death through the interruption of mitosis,
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but the exact mechanism by which apoptosis occurs had not been elucidated in
breast cancer cells treated with paclitaxel. Sunters et al. demonstrated a role for
nuclear FOXO3a in the induction of paclitaxel-induced apoptosis by FOXO3a’s
upregulation of the proapoptotic protein, Bim (Sunters et al., 2003). In order to
investigate this mechanism further, the same group utilized MCF7 cells treated
with paclitaxel and demonstrated a dose-dependent increase in nuclear
localization of FOXO3a (Sunters et al., 2006). The nuclear localization of
FOXO3a was accompanied by decreased Akt signaling but increased c-Jun
NH2-terminal kinase 1/2 (JNK1/2) and p38 activity. Akt is a prosurvival factor
while p38 and JNK are both implicated in apoptosis. This allowed them to
conclude that breast cancer cell death initiated by paclitaxel is dependent on JNK
activation, which results in Akt inhibition and an increase in nuclear/activated
FOXO3a.
Additionally, FOXO3a is suggested to induce apoptosis in breast cancer cells in
response to the cancer treatment drug doxorubicin (Ho et al., 2012). In cases of
breast cancer that are advanced or metastatic, anthracycline derivatives such as
doxorubicin or epirubicin have been utilized as a more aggressive option over
hormone targeted therapies. These drugs induce cell cycle arrest and cell death
by apoptosis, but long-term use leads to an acquired drug resistance (Wong and
Goodin, 2009). Doxorubicin functions by inhibiting topoisomerase II, which
functions in DNA replication, and also by producing free radicals. Both these
effects result in apoptosis. Doxorubicin was shown to induce cell death in MCF7
cells through phosphorylation of FOXO3a on Ser7 (Ho et al., 2012).
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Phosphorylation at this site causes FOXO3a to be localized to the nucleus and
function as a proapoptotic transcription factor. Previous data demonstrated that
paclitaxel induced JNK activation and Akt inactivation in MCF7 cells results in
nuclear localization of FOXO3a (Sunters et al., 2006). p38 was implicated
because of its increased activity; however its exact role in FOXO3a nuclear
localization had not been elucidated. p38 MAPKs are responsive to stress
stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock,
and are involved in cell differentiation, apoptosis and autophagy. Ho et al.
demonstrated a direct interaction between p38 and FOXO3a, and that p38 binds
and phosphorylates a recombinant FOXO3a in vitro (Ho et al., 2012). Utilizing
HPLC and mass spectrometry, Ser7 was identified as the site for p38
phosphorylation and that this site was phosphorylated in response to
doxorubicin. Importantly, they also demonstrated FOXO3a nuclear localization in
response to doxorubicin, and that p38 and Ser7 phosphorylation were required
for nuclear localization by p38. These examples demonstrate that the
proapoptotic transcription factor FOXO3a is activated by certain
chemotherapeutic drugs utilized in breast cancer treatments.
Nuclear exclusion and inactivation of FOXO3a is a consequence of the activation
of prosurvival pathways such as the PI3Kinase/Akt pathway (Brunet et al., 1999).
A study in 2004 attempted to correlate Akt activation with FOXO3a cytoplasmic
localization in primary tumors (Hu et al., 2004). The levels of FOXO3a and
phospho-Akt were examined in 131 human primary breast tumor specimens
using IHC staining and found that FOXO3a was mostly cytoplasmic in tumor
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tissues with high levels of phospho-Akt. Additionally, in tumors with negative
phospho-Akt, FOXO3a was mostly nuclear. Surprisingly, they also detected
FOXO3a cytoplasmic localization in tumor samples that were not positive for
phospho-Akt, suggesting an additional mechanism for the nuclear exclusion of
FOXO3a in these samples. The IκB kinase (IKK) signaling pathway has been
established as an anti-apoptotic pathway. IKK phosphorylates the inhibitory IκBα
protein, resulting in the dissociation of IκBα from NF-κB. NF-κB can then
translocate to the nucleus and activate gene expression, including the
upregulation of certain tumorigenic or angiogenic factors, chemokines, adhesion
proteins, as well as inhibitors of apoptosis. Constitutive activation of IKK and NFκB in human breast cancer cell lines and other primary tumors has confirmed its
role in tumorigenesis (Karin et al., 2002). Because of the IKK/NF-κB pathway’s
role in tumorigenesis, it was thought to be potentially involved in FOXO3a
regulation. Hu et al. found that high levels of nuclear FOXO3a are correlated
with low levels of IKKβ in the human breast tumor specimens and that this
positively correlates with the survival rate in breast cancer (Hu et al., 2004). This
work demonstrated that IKK, independent of Akt, can phosphorylate FOXO3a,
excluding it from the nucleus which promotes cell proliferation and tumorigenesis
in breast cancer cells.
Because FOXO3a localization can predict whether a cell is in a prosurvival or
proapoptotic state, its regulation has been more extensively investigated and its
relation to cancer has become increasingly important. However, there has been
conflicting evidence in recent studies with respect to FOXO3a’s localization and
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breast cancer prognostic outcomes (Chen et al., 2010; Habashy et al., 2011)
(Jiang et al., 2013). In 2010, Chen et al. showed that nuclear FOXO3a was
associated with lymph node positivity, poor prognosis, and phospho-Akt
expression in invasive ductal carcinoma (Chen et al., 2010). They also reported
nuclear FOXO3a in doxorubicin-resistant cells, and that overexpression of
FOXO3a enhances PI3Kinase/Akt activity and promotes cell proliferation.
Activated Akt failed to inactivate and re-localize FOXO3a to the cytoplasm, and
nuclear FOXO3a did not function as a proapoptotic transcription factor. In
contrast, Hashaby et al. were able to correlate poor prognosis with cytoplasmic
FOXO3a which was also associated with PIKC3A, a constitutively active
PI3Kinase mutation linked to breast cancer (Habashy et al., 2011). They
proposed that localization is indicative of function and evidence was provided
that nuclear localization correlates with good prognosis as well as increased
expression of the cell cycle inhibitor, p27. Nuclear localization was also
associated with markers of good prognosis such as FHIT (fragile histidine triad
protein) and PR (progesterone receptor). Additionally, luminal-like breast
cancers expressing nuclear FOXO3a were characterized by low proliferation as
indicated by low mitotic frequency and low MIB1 (proliferation marker)
expression. In a later study, FOXO3a expression was examined by IHC in breast
cancer patient tissue samples and correlated with disease markers such as
tumor size, histologic grade, receptor status and overall patient survival (Jiang et
al., 2013). To determine if FOXO3a expression itself could be a useful
prognostic marker, a Kaplan-Meier analysis was employed to correlate FOXO3a
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expression in tumors with overall survival. It was concluded that patients with
higher FOXO3a expression showed increased overall survival compared with
those who had low FOXO3a-expressing tumors. ER+/FOXO3a+ patients also
had better prognoses than those who were ER-/FOXO3a+, which agreed with a
previous study that indicated that ER is required for FOXO3a inhibition of cell
proliferation (Zou et al., 2008). These conflicting results suggest the need for
further studies investigating the relationship between FOXO3a
localization/expression and its prognostic utility in breast cancer.
In the current study, we provide evidence indicating that E2 and G-1 decrease
apoptosis in MCF7 breast cancer cells over longer time periods in vitro. We
hypothesize that this evasion of apoptosis is a result of inactivation of FOXO3a
and that GPER is responsible. These results provide further indication that
GPER expression should be utilized as a prognostic factor and a target in breast
cancer treatment. Targeting FOXO3a and enhancing its activity could also be a
potential treatment option.
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3.3. Future directions

Our results suggest that the rapid signaling effects of E2 in MCF7 cells are
attributed at least in part to the G-protein coupled estrogen receptor (GPER). To
determine E2’s maximum rapid signaling effects of GPER stimulation on Akt
activation, phospho-Akt levels in MCF7 cells should be evaluated at longer time
points (30 minutes, 45 minutes and 1 hour or more after E2 exposure). We
hypothesize that there may be a peak rapid accumulation of phospho-Akt in
response to E2 before the previously published significant increase at 72 hours
(Lee et al., 2005). Rapid activation of Akt by E2 can lead to prosurvival signaling
and potentially to changes in gene expression. Elucidating the downstream
genomic effects that occur as a result of rapid signaling by E2 can provide
potential targets for inhibiting cell proliferation and survival of breast cancer cells
expressing GPER. Furthermore, we propose that siRNA knockdown of ERα in
MCF7 cells can delineate GPER’s role in rapid activation of Akt, and this would
help to further elucidate its downstream prosurvival effects in response to rapid
activation by E2.
Phospho-Akt levels were monitored in whole cell lysates by Western Blot
analysis, which makes it difficult to elucidate Akt activation on a cellular and
subcellular level. In order to further define the localization of phospho-Akt in
response to estrogen receptor stimulation, Akt activation would need to be
monitored on a cellular level. Localization of phospho-Akt upon activation would
confirm our total Akt localization results and aid in interpreting the mechanism by
which E2 activates this prosurvival pathway in MCF7 cells.
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Activated Akt can phosphorylate FOXO3a at three specific sites: Thr32, Ser253
and Ser315. A constitutively active mutant where all three Akt phosphorylation
sites are mutated to alanine (FOXO3a-TM) exists to monitor FOXO3a’s function
as a proapoptotic transcription factor under any conditions. To further confirm
that GPER stimulation leads to Akt activation resulting in FOXO3a
phosphorylation and inactivation, FOXO3a-TM could be utilized. FOXO3a-TM
cannot be phosphorylated by Akt, therefore we would expect that E2 would not
be able to lead to inactivation of FOXO3a-TM, leading to the inability of E2 to
reverse the pro-apoptotic effects of FOXO3a.
We provided evidence for GPER activation resulting in the inactivation of FoxO3GFP in MCF7 cells. To determine whether this affects protein expression levels
of Bim and p27, which are regulated by activated FOXO3a, we monitored Bim
and p27 protein levels by Western blot analysis. There was no detectable
decrease in Bim or p27 in response to GPER stimulation. To correlate a
decrease in these protein levels with inactivation of FOXO3a on a cellular level,
we propose monitoring Bim and p27 levels by utilizing immunofluorescence
techniques in combination with FoxO3-GFP expression. In MCF7 cells that have
cytoplasmic/inactivated FoxO3-GFP in response to E2, we hypothesize that less
Bim and p27 would be expressed. This would provide direct evidence for GPER
inactivation of FoxO3-GFP resulting in a decrease of the proapoptotic protein
Bim and the cell cycle inhibitor p27. The expected results could further
demonstrate the benefit of inhibiting GPER and thereby blocking its ability to
inactivate FOXO3a.
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Doxorubicin is a chemotherapeutic drug frequently used to treat breast cancer
and has been previously demonstrated to utilize FOXO3a in order to initiate
apoptosis in MCF7 cells (Ho et al., 2012). Doxorubicin targets rapidly dividing
cells by inhibiting topoisomerase II, which results in cancer cell death as well as
healthy cell death leading to extensive side effects. We hypothesize that GPER
is potentially antagonizing doxorubicin’s function by promoting cell survival
through inactivation of FOXO3a. In order to investigate this hypothesis, we
would need to determine whether estrogen opposes the effects of doxorubicin or
other chemotherapy drugs in breast cancer cells via FOXO3a inactivation.
Utilizing FOXO3a’s translocation properties, varying concentrations of E2 would
be added to MCF7 cells in the presence of varying concentrations of doxorubicin.
We would determine the lowest concentration of Doxorubicin where FOXO3a is
still localized to the nucleus in the presence of E2. If a lower dose of doxorubicin
could be utilized in combination with an antagonist of GPER for treatment and
still be effective in FOXO3a nuclear activation, this could concomitantly decrease
cancer drug therapeutic side effects.
To further investigate the clinical relevance of GPER’s inactivation of FOXO3a,
we propose analyzing FOXO3a localization in normal human breast tissue
samples in response to estrogen receptor activation. We would utilize normal
human breast tissue that was previously treated with EGF, G-1, and E2 in organ
culture, followed by fixation with paraformaldehyde (4%). After fixation, the
tissue is paraffin embedded and sectioned. FOXO3a localization would be
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analyzed with IHC and IF in these treated sections to determine whether EGF, G1 and E2 inactivate FOXO3a in human tissue.
Based on the results we provide in this study, further studies correlating GPER
with FOXO3a expression, and FOXO3a localization could potentially
demonstrate the necessity for including these proteins as prognostic factors in
cancer. Although 60% of ovarian cancers are ERα positive, this type of cancer
has a lower response to antiestrogen therapies compared to breast cancer (Ho,
2003). This suggests that estrogen mediates some of its effects in ovarian
cancer through an alternative mechanism. Ovarian tumor samples have been
previously characterized in our lab for their GPER expression, which was
correlated with poor survival (Smith et al., 2009). In our current studies we
provide evidence for GPER activation resulting in FOXO3a inactivation and
cytoplasmic localization. Analyzing these ovarian tumor samples for FOXO3a
localization would help us to determine whether cytoplasmic, inactive FOXO3a is
correlated with GPER expression in human tumor tissue. By analyzing FOXO3a
in tissue and tumor samples, we hope to correlate its localization with patient
outcome. Based on our hypothesis, we would expect nuclear FOXO3a to be
correlated with better outcome and decreased GPER expression.
In summary, our findings indicate one mechanism by which breast cancer cells
can evade apoptosis. Our model proposes that FOXO3a is inactivated by GPER
activation which downregulates the production of proapoptotic genes and results
in cell survival (Figure 3.1).
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Figure 3.1. Proposed model of FOXO3a inactivation by estrogen. Estrogen
stimulates GPER leading to Akt activation. Akt phosphorylates FOXO3a causing
its inactivation, translocation to the cytoplasm and subsequent degradation.
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